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ABSTRACT
Pencil beam scanning (PBS) is a specialized form of proton therapy that utilizes inverse
planning in conjunction with intensity modulation of proton beam spots for treatment delivery.
In recent years, PBS has seen widespread adoption among the proton therapy community and
most newly constructed proton therapy facilities utilize this modality. Due to the widespread
adoption of PBS, there has been considerable effort by commercial and institutional entities to
improve the efficacy of this form of proton therapy. Although there have been numerous
advancements in the clinical use of PBS, many improvements are ongoing or have yet to be
implemented clinically.
The purpose of this doctoral thesis is to explore clinically relevant improvements and
technological advancements for PBS treatments. The work presented in this thesis first
highlights recent technological advancements that are aimed at improving the quality of PBS
delivery for the treatment of cancer. Next, multiple novel clinical translational research projects
carried out at the Seattle Cancer Care Alliance Proton Therapy Center (SCCAPTC) will be
presented. The aim of this work is to explore various approaches to improve and advance the
efficacy of PBS for the treatment of cancer. The numerous strategies for improving PBS
delivery presented in this work can be divided into two general categories: (1) delivery
strategies and (2) computational methods.
The first topic dealing with delivery strategies for PBS describes the validation and clinical
implementation of aperture collimators for PBS as a delivery method to sharpen lateral
penumbra. Reduction of lateral penumbra for PBS improves dose conformality and enables
enhanced dosimetric sparing of critical organs at risk adjacent to the treatment target. Next,
work carried out for validation and clinical implementation of chair-based PBS treatments
using a commercial treatment planning system is presented. Treatment in the seated position
can aid particle therapy centers with fixed beamlines by allowing more flexibility in patient
positioning/orientation thus facilitating an increased number of available beam angles available
for treatment.
On the topic of advancing computational methods for PBS delivery, this work first investigates
comparisons between analytical and Monte Carlo dose calculation algorithms for the treatment
of lung cancer. This work highlights the importance of utilizing Monte Carlo dose calculation
for PBS treatments of targets in highly heterogenous media. Next, this work explores and
12

characterizes the delivery error of PBS treatments through analysis of irradiation log-files. Data
extracted from irradiation log files was then used to develop a computational framework for
delivery error prediction within a commercial treatment planning system using machine
learning.
In presenting highly relevant clinical research, the overall aim of this doctoral thesis is to
disseminate these technological advancements with the hope that they can be translated into
clinical use among the broader proton therapy community and contribute to the improvement
of PBS treatments.
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CHAPTER 1: INTRODUCTION
1.1 Overview
The use of high energy protons for the treatment of cancer was first proposed by Dr. Robert
Wilson in 1946 (1). Almost a decade later, some of the first patients to receive proton therapy
were treated at the Berkley Radiation Laboratory in 1954 (2). For the next several decades, use
of proton therapy was limited to research laboratories including Los Alamos National
Laboratory and Harvard University. The first hospital-based proton therapy center was the
Loma Linda University Proton Therapy Center in California and was established in 1988
following approval of proton therapy by the U.S. Food and Drug Administration (2). Over the
next two decades, many additional hospital-based proton therapy centers were established with
Massachusetts General Hospital, MD Anderson Proton Center and the Midwest Proton
Therapy Institute being among the early developments.
More recently, PBS has gained widespread use and has become the standard of care among
most modern proton therapy facilities. PBS, also known as spot scanning, was first
implemented clinically at the Paul Scherrer Institute in Switzerland (PSI) in 1990 (3). Unlike
proton therapy delivery techniques such as double scattering (DS) and uniform scanning (US)
(4, 5), PBS does not require the use of beamline scattering devices for field modulation or
patient-specific apertures/compensators for beam shaping. Instead, in PBS delivery, scanning
magnets are used to steer the proton beam and irradiate beam spots across the tumor volume as
shown in Figure 1.1.

Figure 1.1. Diagram of a proton PBS nozzle irradiating a target. Image taken from Hall (6).

PBS beam spots are delivered in layers with each layer corresponding to a specific energy.
Furthermore, the intensity of each beam spot can be varied allowing for superior dose
conformality compared to US/DS for certain disease sites (7-10). The widespread adoption of
14

PBS by many new and future clinics has been a major technological advancement for proton
beam therapy.
Despite the advantages of PBS over other proton therapy modalities such as US and DS, there
remain numerous improvements to be made that can positively impact the quality and accuracy
of PBS delivery for patient treatments. Development and improvement of PBS technology is
an active area of research and many studies have been published on this topic since PBS was
first implemented clinically at PSI. The research in this doctoral thesis will focus on
technological advancements and contribute novel studies to the existing literature.

1.2 Aims/Chapter Outlines
Aim 1: Investigation and implementation of aperture collimators for PBS
Chapter 3 explores the utilization of aperture collimators for PBS treatments. This chapter
begins by characterizing the lateral falloff of PBS beams with and without use of an aperture
as a function of various beam parameters. This chapter aims to provide clinical guidance to the
broader proton therapy community regarding use of apertures for PBS by characterizing
aperture-collimated PBS penumbra as a function of various beam characteristics. Finally, this
chapter will describe commissioning and validation of aperture collimators for PBS treatments
using a commercial treatment planning system (TPS).
Aim 2: Clinical validation of PBS treatments in the seated position
Chapter 4 presents the clinical validation and implementation of a chair in a commercial TPS
for PBS treatments with the patient in the seated position. Treatment in the seated position
addresses the limitation of available beam angles when treating in a fixed proton beamline. The
goal of this chapter is then to present the commissioning and clinical implementation of
treatments in the seated position within a commercial TPS. This work can serve as a basis for
implementation of chair-based treatments which is a useful topic for proton therapy clinics that
are faced with the beam angle limitations of a fixed beamline.
Aim 3: Comparisons of PB and MC dose calculation in lung
Chapter 5 first reviews the performance and accuracy of pencil beam (PB) and Monte Carlo
(MC) dose calculation algorithms for PBS as implemented in a commercial TPS. This chapter
highlights the deficiencies of PB algorithms compared to MC especially in the presence of
15

highly heterogeneous media. Next, differences in PBS dose distributions between PB and MC
calculated treatment plans for a cohort of lung cancer patients was investigated. This was
carried out through a comparative dosimetric analysis between commercial implementations
of MC and PB dose engines performed on these ten patient plans. The aim of this chapter is to
highlight the importance of using MC dose calculation for the treatment of lung cancer.
Aim 4: Application of machine learning for prediction of PBS delivery error
Chapter 6 investigates the novel use of machine learning (ML) models for delivery error
prediction in PBS delivery. The work in this chapter utilized irradiation log-files which contain
delivered spot parameters including spot position and MU for PBS fields following beam
delivery. Delivered spot parameters from the log-files were first compared to the planned
parameters extracted from the TPS for a set of previously-treated prostate patients.
Characterization of spot position and MU delivery error was carried out as well as the
dosimetric impact of this delivery error on a test prostate patient. Next, this dataset of planned
parameters from the TPS and delivered parameters from the log-files was used as a training
dataset for three ML models which were trained to predict delivered spot parameters based on
planned parameters. Of the three ML models that were tested in this study, it was concluded
that the random forest regression model performed the best in prediction of delivered spot
parameters compared to linear regression and neural network model. The main objective of this
chapter is to demonstrate to the reader that (1) delivery errors in PBS beams can impact
treatment plans and (2) ML models can be trained to predict this delivery error.

1.3 Contributions and Publications

Peer-Reviewed Publications:
1) Maes D, Bowen SR, Regmi R, Bloch C, Wong T, Rosenfeld A, Saini J. A machine
learning-based framework for delivery error prediction in proton pencil beam scanning
using
irradiation
log-files.
Phys
Med.
2020
Oct;78:179-186.
doi:
10.1016/j.ejmp.2020.09.008. Epub 2020 Oct 7. PMID: 33038643.
2) Maes D, Janson M, Regmi R, Egan A, Rosenfeld A, Bloch C, Wong T, Saini J. Validation
and practical implementation of seated position radiotherapy in a commercial TPS for
proton therapy. Phys Med. 2020 Nov 11;80:175-185. doi: 10.1016/j.ejmp.2020.10.027.
Epub ahead of print. PMID: 33189048.
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3) Maes D, Regmi R, Taddei P, Bloch C, Bowen S, Nevitt A, et al. Parametric characterization
of penumbra reduction for aperture-collimated pencil beam scanning (PBS) proton therapy.
Biomedical Physics & Engineering Express. 2019;5(3):035002.
4) Maes D, Saini J, Zeng J, Rengan R, Wong T, Bowen SR. Advanced proton beam dosimetry
part II: Monte Carlo vs. pencil beam-based planning for lung cancer. Translational lung
cancer research. 2018;7(2):114-21.
5) Saini J, Traneus E, Maes D, Regmi R, Bowen SR, Bloch C, et al. Advanced Proton Beam
Dosimetry Part I: review and performance evaluation of dose calculation algorithms. Transl
Lung Cancer Res. 2018;7(2):171-9.
Presentations & Published Abstracts:
1)

Saini J, Maes D, Bowen SR, Egan AJ, Bloch C, Wong TP. A Comparison between
Pencil Beam and Monte Carlo Algorithms against Film Measurements in an
Anthropomorphic Phantom for Proton Spot Scanning. International Journal of
Radiation Oncology • Biology • Physics. 2017;99(2):E717-E8.

2)

Fung, A., Saini, J., Maes, D., Fang, C., Wong, T. (2017) “Dose comparison between
pencil beam and Monte Carlo calculation algorithm in left chest wall patients.” Int. J.
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CHAPTER 2: LITERATURE REVIEW
2.1 Use of aperture collimators for PBS
Proton PBS allows for highly conformal treatment deliveries, minimizing dose to surrounding
tissue (11, 12). This is accomplished by careful placement of spots tightly around the target
volume in a way that limits dose to healthy tissue (12). Other proton beam delivery techniques
such as DS utilize aperture collimation for field shaping which results in sharper lateral
penumbra than PBS without apertures. Recently, the Raystation TPS (Raysearch Laboratories,
Stockholm, Sweden) has coupled the strengths of each delivery technique by adding the
application of apertures to PBS fields (11, 13, 14). While PBS delivery has traditionally been
delivered without the application of apertures, the use of aperture collimation can reduce lateral
penumbra and, therefore, minimize dose to critical organs at risk for certain disease sites (15).
Various studies have been conducted investigating the use of apertures in PBS beam delivery.
One of the first studies dealing with the collimation of PBS beams for reduction of lateral
penumbra was presented by Bues et al. (16). In this study a proton multi-leaf collimator (MLC)
was modeled using the MCNPX MC code and the lateral penumbra (80%-20% distance) of
PBS beams was analyzed with and without MLC collimation. This study showed a proton MLC
can sharpen the lateral penumbra of a PBS beam up to 1cm for shallow depths as seen in the
figure below (16).

Figure 2.1. Plot showing penumbra of an un-collimated and MLC-collimated proton beam where the x and y
axis are penumbra width (80%-20% distance in cm) and proton beam range respectively. Image taken from
Bues, Newhauser (16).
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At deeper depths however, the lateral penumbra for a collimated PBS beam can exceed that of
an un-collimated beam as shown in Figure 2.1 (16).
In another study by Safai et al., analytical formulas were presented to describe the lateral
penumbra between a collimated DS beam and un-collimated PBS beam using various
collimator-to-surface distances, proton ranges and PBS spot sizes (17). These formulas were
validated against profile measurements using an ionization chamber and were found to have an
accuracy of 3% for depths larger than 7.6 cm. Results from the analytic formulas and
measurements indicate that the penumbra of a pencil beam at shallow depths is larger than the
penumbra of a collimated DS beam, but better at larger depths as shown in Figure 2.2 (17).

Figure 2.2. Plot comparing the penumbra of a DS and un-collimated PBS beam. Image taken from Safai,
Bortfeld (17).

It is therefore concluded by Safai et al. that aperture collimation should be considered for PBS
delivery for shallow targets (17).
Another study by Dowdell et al. analyzed the out-of-field dose of a DS proton beam compared
to a collimated and un-collimated PBS beam using the GEANT4 MC toolkit (18). In this work,
Dowdell et al. demonstrated that PBS has an overall lower out-of-field dose compared to DS
across multiple depths. Furthermore, the out-of-field dose for a PBS beam can be reduced
through the use of a aperture as shown in Figure 2.3 (18).
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Figure 2.3. Out-field dose (left) and equivalent dose (right) for a DS beam (square), un-collimated PBS beam
(circle) and collimated PBS beam (triangle) at a depth of 28.32 cm in water. Image taken from Dowdell, Clasie
(18).

Use of an aperture results in the creation of secondary neutrons generated during the interaction
of the PBS beam spots and the aperture. However, even though secondary neutron fluence is
increased when using an aperture, a collimated PBS beam still results in lower out-field-dose
compared to an un-collimated PBS beam. This is primarily due to the removal of large angle
scatter when an aperture is applied (18).
More recently Charlwood et al. performed MC simulations of a PBS nozzle using the GEANT4
application for tomographic emission code (GATE) (15). In this study, the lateral penumbra of
collimated and un-collimated PBS beams was analyzed against several parameters which
included nozzle-to-surface distance, vacuum window-to-surface distance and range shifter
thickness. Figure 2.4 shows penumbra width as a function of depth for un-collimated (blue)
and collimated (red) PBS beams without a range shifter (a) and with a range shifter (b) using a
10 cm thick range shifter and airgap of 8.5 cm from the water phantom surface (15).
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Figure 2.4. Plot of an un-collimated (blue) and collimated (red) PBS beam with and without range shifter for
various energies. Image taken from Charlwood, Aitkenhead (15).

This study found that adding collimation to a PBS beam can sharpen the lateral penumbra by
2 – 4 mm depending on depth. Furthermore, the lateral penumbra of an un-collimated PBS
beam is particularly sensitive to nozzle-to-surface distance as well as whether or not a range
shifter is used (15).
Another study by Winterhalter et al. characterized the lateral penumbra of PBS beams with and
without aperture collimation using the tool for particle simulation (TOPAS) (19) MC toolkit
(20). In this study three optimization techniques were implemented: edge-collimated uniformly
weighted spots (collimation), pencil beam optimization of un-collimated pencil beams (edgeenhancement) and the optimization of edge collimated pencil beams (collimated edgeenhancement) (20). Using these three optimization techniques, the lateral penumbra of PBS
beams was evaluated across different range shifter thicknesses and airgaps. Furthermore, this
study analyzed the effect on lateral penumbra by placing the aperture upstream and downstream
of the range shifter. The study by Winterhalter et al. concluded that the sharpest lateral
penumbra can be achieved by using collimated edge enhancement combined with an aperture
positioned upstream from the range shifter (20).
Baumer et al. carried out a similar study to that of Winterhalter et al. and investigated the lateral
penumbra of a PBS beam with the aperture placed upstream and downstream from the range
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shifter (21). Furthermore, the lateral penumbra of a collimated PBS beam was compared to that
of a DS proton beam. DS and PBS treatment plans were generated using the Raystation TPS.
The TPS-calculated penumbra values were also validated against measurements using a
scintillation detector and ionization chamber. Finally, DS and collimated PBS treatment plans
were generated on a clinical CT scan of a target located in an ocular orbit. Interestingly, the
study by Baumer et al. differed with that of Winterhalter et al. and concluded that the lateral
penumbra of a PBS beam is approximately 20% less when the aperture is positioned
downstream from the range shifter (21). As mentioned by Baumer et al., differences in
conclusions between these two studies can be attributed to multiple factors including differing
beamline components as well as range of energies studied (21). Furthermore, based on phantom
data, this study also concludes that the lateral penumbra of a collimated PBS beam is larger
than for a DS proton beam.
More recently, Grewal et al. reported on penumbra sharpening and scattering of the adaptive
aperture (AA) as implemented with the Mevion S250i compact pencil beam scanning proton
therapy system (22). In this work, field edges were analyzed with film and scintillation
detectors to characterize beam penumbra as a function of energy, and airgap. Measurements
were carried out in solid water at various depths with film and in air with the scintillation
detector. Finally, the dosimetric effects on clinical treatment plans were evaluated with plans
optimized using AA and open fields. The study concluded that compared to open fields, in-air
penumbra was reduced by 30-60% when using AA for treatment planning. At treatment depth,
measurements carried out with film showed 10 to 14 mm of penumbra reduction when using
AA (22). Note that the Mevion PBS system as described in Grewal et al. has spot sigma values
that range from 3.8 mm to 29.4 mm for proton spot energies of 227.15 MeV and 33.04 MeV
respectively. This is due to a series of range modulators located in the nozzle which induce
increasingly larger angle scattering at lower energies. Due to these relatively larger spot sizes
at lower energies, use of use aperture collimation such as AA is particularly important for
maintaining optimal dose conformality for PBS delivery using the Mevion system presented in
this work.

2.2 Chair-based treatments in radiotherapy
Radiotherapy in the seated position has been an active area of investigation for many years and
some of the earliest published studies on this topic date back to the 1950’s. More recently
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however, implementation of chair-based radiotherapy has become a very active area of research
among particle therapy centers. Due the prohibitive cost of constructing a full rotational gantry
for a particle therapy beamline, many proton and heavy ion centers have opted to construct one
or more fixed beamlines. Although fixed beamlines are more compact and require less
resources to construct, available beam angles for these types of treatment rooms are limited
when patients are treated on a conventional treatment couch in the supine position. For this
reason, utilization of a rotational treatment chair with the patient immobilized in the seated
position allows for the availability of more beam angles when treating in a fixed proton and/or
heavy ion beamline.
Rahim et al. has presented a historical view of this subject and summarized many of the studies
in Figure 2.5 shown below (23).

Figure 2.5. Various publications reporting on radiotherapy treatment chair apparatuses from 1956 to 2017.
Image modified from Rahim et al. (23).

Many of the chairs shown in Figure 2.5 were designed for use with external beam photon
therapy (24-32).
Some of the motivations for treating in the seated position include improved patient comfort as
well as improved OAR sparing for certain disease sites. For example, Duisters et al.
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demonstrated high reproducibility of patient positioning as well as increased comfort for lung
cancer patients (31). In this study a novel treatment chair with design characteristics optimized
for lung cancer treatments was fabricated to allow for patient immobilization in the seated
position (see Figure 2.6).

Figure 2.6. Custom-designed treatment chair for radiotherapy in the seated
position. Image taken from Duisters, Beurskens (31).

In this study a cohort of 10 lung cancer patients was utilized to study the comfort and
reproducibility of patient positioning and immobilization. To study these quantities patients
were simulated on a conventional simulator in the supine and seated positions multiple times.
Patients were also asked which treatment position they felt was more comfortable. Results of
this study indicate that setup reproducibility was within 1 cm in both the seated and supine
positions. Regarding comfort, all 10 patients reported that the seated position was superior
compared to the supine setup. More interestingly there was significant change in the measured
lung volume across the patient cohort between the two patient positions with the seated position
corresponding to larger average total lung volume (3914 cm3 seated vs. 3162 cm3 supine) (31).
This increase in lung volume in the seated position also led to a decrease in the irradiated lung
volume based on analysis of test plans created in a TPS utilizing 10 MV photons to deliver 30
Gy with a LINAC (31) although it is unclear if this same effect would be observed in the case
of proton therapy.
As mentioned earlier, development of treatment chairs is also an active area of interest among
particle therapy centers in which fixed beamlines are commonly utilized for treatment. In a
recent study Sheng et al. reported on the performance of a treatment chair designed for use in
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fixed therapeutic particle beamlines (33). In this work, a chair was fabricated and mounted to
a robotic 6DOF platform allowing for patient positioning at multiple orientations in the seated
position.

Figure 2.7. Patient in the seated position on a custom-made treatment chair on rails in front of a fixed particle
therapy beamline. Image taken from Sheng, Sun (34).

As part of this study Sheng et al. investigated the positional accuracy and stability of the
treatment chair using a motion capture system. Analysis of the positional accuracy of the chair
showed all relevant positional parameters well within acceptable limits and were similar in
magnitude to a clinically validated in-room robotic treatment couch. The reported positional
and rotational accuracy of the chair were ± 0.12 mm and ± 0.04° respectively (34).
In another study Buchner et al. presented a robotic chair which was designed for a compact
proton therapy system and allowed for patient treatments in three positions: (1) sitting, (2)
reclined and (3) lying/supine as shown in Figure 2.8 (35).
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Figure 2.8. Illustration of a robotic chair used for a compact proton therapy system. The chair allows for the
patient to be sitting (a), reclining (b) and lying. Image taken from Buchner, Yan (35).

The prototype chair presented in this study utilized pneumatic immobilization units which were
placed around the patient’s waist and shoulders. To evaluate patient setup stability in the chair,
Buchner et al. employed a group of human volunteers. Each of these volunteers were
immobilized in the treatment chair and their motion was tracked using a surface guidance
device to monitor positional and rotational movements over time. Figure 2.9 shows the stability
of a test patient setup over time freely sitting and immobilized compared to a clinical setup
tolerance of 1 mm (translational) 0.5° (rotational) (35).

Figure 2.9. Positional and rotational movements of a single test patient immobilized in the treatment over a 500
sec. interval while freely sitting (pink) and immobilized (blue) compared to clinical reference tolerance of
1mm/0.5° (dotted line). The top row shoes translational movements along the patient right-left (ΔTx), superiorinferior (ΔTx) and anterior-posterior (ΔTz) directions. The bottom row shows rotation displacements in pitch
(ΔRx) roll (ΔRy) and yaw (ΔRz). Image taken from Buchner, Yan (35).

Results of this study show that the treatment chair can achieve suitable setup accuracy for
proton therapy treatments while allowing for a multitude of patient positions and orientations.

2.3 Improvements in PBS dose calculation algorithms
Incorporation of MC into treatment planning has been among the most significant
advancements in proton therapy dose calculation. Multiple studies have been conducted
demonstrating the superior dose calculation accuracy of MC compared to the analytical pencil
beam (PB) dose calculation algorithm for certain disease sites (36-44). Traditionally, PB has
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been the standard of care in proton therapy dose calculation and until recently this was the only
dose calculation algorithm implemented in commercial TPSs. Many modern PB dose engines
are based on the works of Hong et al. (45) and Schaffner et al. (46) and offer fast and efficient
dose calculation at the cost of reduced accuracy especially in the presence of complex
heterogeneities.
In PB, PBS beams are decomposed into multiple beamlets often referred to as pencil beams.
Furthermore, PB dose engines typically approximate a medium as a series of infinite
homogeneous slabs where each of these slabs takes on a composition equal to the material
composition encountered along the central axis of each beamlet at a given depth (47). For this
reason, PB dose engines can yield sufficient accuracy in a homogenous environment. However,
in the presence of complex geometries or heterogeneous environments, these algorithms can
yield substantial errors in dose calculation. Further errors can result from an inability of PB
dose calculation to correctly model elastic Coulomb scattering as well as elastic and inelastic
nuclear interactions (48).
In contrast to PB, MC dose calculation uses individual particle tracking where the outcome of
each particle interaction is determined by sampling probability density distributions (47). In
commercial MC implementations, a clinical beam model will include accurate information
about the phase space of particles at nozzle exit. After exiting the beamline, particles are
transported through a patient CT scan and the deposited energy at any given point due to
particle interactions is scored. This process continues across a sufficiently large number of
particles such that the statistical uncertainty for dose in a voxel is adequate. The statistical
uncertainty of deposited energy in a voxel is inversely proportional to the square root of the
number of simulated primary particles. Therefore, MC dose calculation can be very accurate
provided a sufficient number of simulated particles are transported. For this reason, MC is often
considered the gold standard of dose calculation algorithms (38).
Multiple studies have been carried out investigating differences between MC and PB. In 2012
Paganetti presented a thorough review of range uncertainties in proton therapy using MC and
PB (38). In this study, Paganetti compared dose distributions of a proton beam on a patient CT
using MC and PB and noted differences observed especially in highly heterogeneous regions
such as bone tissue interfaces.
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Figure 2.10. Proton dose distributions calculated with analytical PB (left) and MC (right). Image taken from
Paganetti (38).

As can be seen in Figure 2.10, noticeable differences between PB and MC can be observed
where the proton beam traverses a path tangential to a bone tissue interface. This difference
can be attributed to the inability of PB to accurately model multiple coulomb scattering in
complex heterogonous geometries (38).
In another study Yamashita et al. implemented a GEANT4 framework to compare MC and PB
dose distributions for various disease sites (39). In this work treatment plans were generated
with the XIO TPS which used PB for dose calculation. The treatment plans were then recalculated with MC for brain, prostate, lung and liver targets.
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Figure 2.11. Dose distributions calculated with PB (g) and MC (h) as well as the corresponding gamma
distribution (i) for a lung target. Figures j, k and l show line dose and gamma profiles for figures g, h and i
respectively. Image taken from Yamashita, Akagi (39).

The work conducted in this study showed that significant differences exist between dose
distributions calculated with MC and PB especially in the distal fall-off region. This was
particularly noticed when the proton beam was transported through low density regions as can
be seen in Figure 2.11 (39).
In a more recent study, Grassberger et al. studied differences between PB and MC dose
calculation in a cohort of 19 lung cancer patients treated with proton DS. PB dose calculations
were carried out using a commercial TPS (XIO) and MC simulations were performed with
TOPAS (41).
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Figure 2.12. Dose distributions calculated with PB (C), MC (D) as well as corresponding DVH (E) and
difference plot (F) for a lung tumor. Image taken from Grassberger, Daartz (41).

Treatment plans were created in XIO using PB for all 54 patients. Re-calculating the treatment
plans with MC resulted in a mean dose loss of -2.3% to the CTV. Furthermore, this study
reported that recalculating with MC resulted in a decrease in lung dose for small targets and an
increase in lung dose for large targets. Finally, MC and PB profiles and depth doses were
validated against an ionization chamber array measurement in a lung phantom. Analysis
demonstrated an average difference of 1.6% for MC and 5.6% for PB compared to
measurement (41).
In another study, Taylor et al. investigated differences in dose calculation between MC and PB
using an anthropomorphic lung phantom (49). The lung phantom used in this work was sent to
five separate proton therapy clinics across the USA. At each clinic a CT scan of the lung
phantom was acquired and a hidden target volume within the phantom was delineated. CT
scans were transferred to the TPS of the corresponding clinic and PBS plans were generated to
irradiate the target volume to a given dose level using PB and MC dose calculation. The lung
phantom was equipped with several thermoluminescent dosimeters (TLDs) to measure point
doses as well as gafchromic film to measure profiles. Following PBS beam delivery at each
clinic, the lung phantom was returned to the Imaging and Radiation Oncology Core (IROC)
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where the TLDs and film were analyzed. Figure 2.13 shows dose profiles across the lung
phantom target as measured with film and calculated with MC and PB.

Figure 2.13. Dose profile across the iGTV of an anthropomorphic lung using film (blue) and calculated with two
dose calculation algorithms: MC (red) and PB (green) for four proton therapy clinics. Image taken from Taylor,
Kry (49).

This study showed that treatment plans calculated with PB over-predicted dose to the target
volume by an average of 7.2% compared to measurements. In some regions of the target
volume PB over-predicted dose by up to 46% percent. In contrast, MC-calculated treatment
plans showed a mean agreement within 4% of measurements and maximum difference of 12%
(49).
Finally, Widesott et al. reported on differences between MC and PB dose calculations in a
variety of treatment sites and delivery conditions using the Raystation TPS. (50). In this work,
an anthropomorphic head phantom as well as a biological sample were simulated and used to
create a series of test plans using MC and PB for optimization and dose calculation utilizing
various combinations of planning parameters including air gap, range shifters and gantry
angles. For every plan created in this study, beam measurements with an ion chamber array
were acquired and compared against dose calculations using gamma analysis. Figure 2.14
shows dose differences and line dose profiles between PB and MC dose calculations in a
biological sample (i.e. lamb’s head).
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Figure 2.14. Dose distributions of treatment plan generated with PB dose calculation (upper left) and recalculated using MC (bottom left) as well as corresponding DVH (upper right), dose difference (bottom right)
and line dose profiles (bottom middle). Image taken from Widesott, Lorentini (50).

When compared to the ion chamber measurements, gamma pass rates for MC dose calculation
were on average approximately 10% higher compared to gamma pass rates for PB dose
calculation across multiple treatments created using the biological sample as well as an
anthropomorphic phantom (50). These results agree with other studies mentioned in this
chapter section that demonstrate the superior dose calculation of MC compared to PB.

2.4 Machine learning applications in proton therapy
This section will provide a broad overview of ML applications within radiation oncology while
emphasizing relevant studies dealing with proton therapy and more specifically proton PBS.
Machine learning is a subfield of artificial intelligence that utilizes computational models along
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with statistical methods to make predictions or decisions based on collections of data. Figure
2.15 shows the relationship between the terms artificial intelligence and machine learning.

Figure 2.15. Figure illustrating the relational hierarchy of the following terms: artificial
intelligence, machine learning and deep learning.

As shown in Figure 2.15, within the field of ML is a more specific class of predictive models
that fall under the term of deep learning. Deep learning utilizes specific types of predictive
models often referred to as artificial neural networks which are inspired by the biological
networks of an animal brain. ML models can be classified into three broad learning categories:
(1) supervised learning, (2) unsupervised learning and (3) reinforcement learning as shown in
Figure 2.16.
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Figure 2.16. Illustration of the 3 general types of ML models with corresponding applications types.

As shown in Figure 2.16, unsupervised and supervised learning models can be further
categorized into subclassifications: clustering and dimensionality reduction for unsupervised
leaning algorithms as well as classification and regression for supervised learning models. All
the studies referenced within this section utilize ML models that can be classified into one of
three categories shown in Figure 2.16.

2.4.1 Machine learning for proton MU prediction
One application of ML to proton therapy that been studied in multiple publications is the
prediction of MU for passive scattering proton therapy (PSPT) modalities such as uniform
scanning and double scattering (51) (52). Complexity of various beamline components utilized
in PSPT as well as variability of these components across different PT systems makes a
generalized analytical calculation of MU challenging to implement for commercial TPS
vendors. As most commercial TPSs do not calculate MU values for PSPT, accurate predictions
of this parameter can streamline QA workflow by avoiding the need to carry out patientspecific beam measurements although rigorous validation should be carried out before clinical
use. In one study by Sun et al. a training dataset was compiled that included measured MU,
range, modulation and field size of 1754 beams (51). This data was used to train 3 different
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ML models for the prediction of MU. Prediction accuracy of these three models (Random
Forest, XGCBoost and Cubist) were compared against a semi-empirical model described by
Kooy et al. (53).

Figure 2.17. Histogram plots of the percentage difference (i.e. prediction accuracy) of various ML
models (a, b, c) in the prediction of PSPT MU compared to a semi-empirical model (d). Image
from Sun, Lam (51).

As can be seen in Figure 2.17, all ML models demonstrated superior prediction accuracy
compared to the semi-empirical model with the Cubist model proving the most accurate results
(51). The prediction accuracy presented in Sun et al. is similar in result to the work by Grewal
et al. (52) in which various neural network (NN) architectures were utilized for MU prediction
as shown in Figure 2.18.
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Figure 2.18. Histogram of MU prediction accuracy for 3 different neural network models.
Image from Grewal, Chacko (52).

As can be seen in Figure 2.18 the Gaussian process NN model had the best prediction accuracy
with a mean absolute error (MAE) of 0.61% (52). This gaussian process NN model performed
very similar to the work by Sun et al. which reported a mean absolute error of 0.62% for Cubist
model in the prediction of PSPT MU (51).

2.4.2 Machine learning for CBCT conversion
Another application of ML to PT is the conversion of cone-beam computed tomography
(CBCT) images to make them suitable for proton dose calculation. This is an active area of
research and has been studied extensively (54-59). Due to the Bragg peak, PT dose distributions
exhibit steep distal dose gradients making accurate beam delivery very sensitive to changes in
patient anatomy (54, 60). CBCT images can be a useful imaging modality for adaptive
radiotherapy (ART) within a proton therapy workflow as anatomical change in patient anatomy
can be accurately evaluated (60). However, due to poor image quality, CBCT images are not
suitable for PT dose calculation which drives interest in this topic.
Published work that propose ML solutions in the conversion of CBCT has been summarized
by Wu et al. (61) as shown in Table 2.1.
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CONVERSION

TREATMENT SITE

STRATEGY

USED IN STUDY

Thummerer et al. (54)

CBCT to CT

Head & Neck

U-Net

Kurz et al. (55)

CBCT to CT

Prostate

GAN

Hansen et al. (56)

CBCT to CT

Pelvis

U-Net

Landry et al. (57)

CBCT to CT

Prostate

U-Net

Harms et al. (59)

CBCT to SPR

Head & Neck

GAN

STUDY

NN ARCHETECTURE

Table 2.1. Table summarizing selected works which have presented ML-based methods for CBCT conversion.
Image modified from Wu, Nguyen (61).

All models presented in Table 2.1 are deep neural network (DNN) architectures of two general
types: generative adversarial network (GAN) (62) and U-net (63). The methods employed to
correct CBCTs within these studies fall into two categories: (1) CBCT to CT conversion and
(2) CBCT to relative stopping power (RSP) conversion. In CBCT to CT conversion, models
are trained to predict a map of CT-HU values based on CBCT-HU values. The result is the
generation of a synthetic CT (sCT) which can then be used by a TPS to perform dose
calculation through conversion of cCT values to RSP values. In the second category, CBCT
values are converted to RSP values which can be directly used to calculate dose.
In a study by Thummerer et al. a GAN was trained on 27 H&N patients to predict CT-HU
values based on CBCT-HU values resulting in a synthetic CT (58). The synthetic CT was then
used for dose calculation with the Raystation TPS. Multiple model evaluation metrics were
used including MAE and gamma analysis for assessment of image quality and suitability for
accurate dose calculation respectively. Figure 2.19 shows a CBCT, synthetic CT and clinical
CT for a test patient.
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Figure 2.19. Images of CBCT (left column), synthetic CT created using a GAN
model (labeled as cCT CBCT, middle column) and clinical patient CT (labeled
pCT, right column of a test patient anatomy. Image modified from Thummerer,
de Jong (58).

Results of this work show that the GAN model was able to generate synthetic CTs with MAE
of 40 ± 4 HU compared to clinical CTs. Furthermore, the average gamma pass rate of proton
dose calculations using synthetic vs. clinical CTs was 96.1% using 2%/2mm pass/fail criteria.
A similar study was carried out by Guillaume et al. using multiple U-net models to carry out
corrections of CBCTs for proton and photon dose calculations (57) using clinical data from
prostate scans. This study was able to achieve MAE values of 48/88/56 HU in the prediction
CT values based on a test dataset of CBCT images across three different U-net models. In
Hansen et al. a U-net model was also used for CBCT correction and MAE values of 46 HU
were reported which is similar to Guillaume et al. and Thummerer et al. (56). Gamma pass
rates for proton dose calculations on test patients however were much lower and ranged from
15% to 81% in Hansen et al. (56). Finally Kurtz et al. evaluated the performance of a cycleGAN (64) and found the resulting synthetic CT acceptable for VMAT dose calculation but was
unable to achieve acceptable gamma results for proton dose calculation (55).
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2.4.3 Machine learning for beam delivery error prediction
Numerous studies have also investigated the use of machine learning applications for
prediction of MLC delivery error in conventional photon therapy and it is worthwhile to review
some of these works as well since they relate to the work presented in Chapter 6. In Carlson et
al. it was demonstrated that ML can accurately predict MLC leaf position errors in VMAT
treatment deliveries (65). In this study the planned MLC positions from DICOM-RT files were
compared against delivered positions obtained from LINAC log-file delivery data. Planned and
delivered MLC positions from a previously treated group of 74 patients receiving VMAT
constituted the training dataset for ML models. This data was used for training of 3 different
types of ML models: (1) linear regression, (2) Random Forest (66) and (3) cubist (67). Models
were tested on hold-out plans using MAE and root mean square error (RMSE) of MLC position
prediction as model evaluation metrics. This study concluded that the cubist model
demonstrated the lowest prediction error and performed best at predicting delivered MLC
positions. Figure 2.20 shows the cubist model performance along with delivery error of MLC
positioning for moving MLC leaves and MLC leaves at rest across three different
clinics/LINACs.

Figure 2.20. Mean absolute error of the prediction of MLC
positions during VMAT delivery using three different ML models.
Image taken from Carlson, Park (65).

Predicted MLC positions were also generated and inserted into DICOM-RT files which were
subsequently used for dose re-calculation in the TPS for a set of test patients. 2D dose profiles
were measured with a MapCHECK2 detector array (Sun Nuclear Corporation, Melbourne, FL)
and compared with the planned dose distribution and dose distribution calculated with the
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predicted MLC parameters using gamma analysis. When compared to measurements, predicted
dose distributions had higher gamma rates than planned parameters using pass/fail criteria of
3%/3mm, 2%/2mm and 1%/2mm.
In another study Valdes et al. reported on the use of an analytical model to accurately predict
gamma pass rates of IMRT deliveries based on multiple plan complexity parameters including
MU, MLC leaf positions and LINAC type (68). In this work, 498 IMRT treatments were planed
using the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, California).
Following planning, feature extraction of plan complexity metrics based on MLC leaf
parameters and control point MU values was carried out for each plan. Dose profiles at
standardized depths were measured using a commercial 2D diode array and compared to the
calculated dose from TPS using a 3%/3mm gamma analysis. A dataset comprising of
complexity metrics as well as gamma analysis results for each of the 498 IMRT plans was used
for training of a generalized linear model to predict gamma fail rates using residual error as an
evaluation metric. Model testing was carried on unseen data and the residual error values (i.e.
predicted gamma rate – measured gamma rate) of the trained linear model were within +/- 3%
as shown in Figure 2.21 (68).

Figure 2.21. Histogram plot of the residual error for prediction of gamma fail rate using the generalized
liner model. Image taken from Valdes, Scheuermann (68).

To prevent overfitting and to ensure optimal model generalization to unseen data, Lasso
regularization (69) was employed during model training. The model presented in this study
served as the basis of a virtual IMRT QA framework which can allow for the early detection
of gamma fail rates during the treatment planning stage.
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CHAPTER 3: PENUMBRA REDUCTION FOR
APERTURE-COLLIMATED PENCIL BEAM
SCANNING PROTON THERAPY
The results presented in this chapter have been published in journal of Biomedical Physics &
Engineering Express:

Maes D, Regmi R, Taddei P, Bloch C, Bowen S, Nevitt A, et al. Parametric characterization
of penumbra reduction for aperture-collimated pencil beam scanning (PBS) proton therapy.
Biomedical Physics & Engineering Express. 2019;5(3):035002.
Author Contributions:
This project was led and organized by DM. DM performed the measurements and data
collection with assistance from ZN and EL. Figures and text were composed by DM in
consultation with AR, JS, TW, PT and CB.

3.1 Introduction
This chapter will present work on improving PBS treatments using aperture collimators. The
work presented in this chapter is impactful as it has served as the basis of clinical
implementation of aperture-collimated PBS treatments at the SCCAPTC and to date numerous
patients have received treatment using this technique. The motivation for using aperture
collimators for PBS are enhanced dose sparing of OARs adjacent to the target through
penumbra sharpening as described in Chapter 2. The research analysis presented in this chapter
is also novel as it was the first to comprehensively characterize lateral penumbra and validate
its dose calculation across all relevant treatment planning parameters using a commercial TPS.
Multiple studies have been carried out on the topic of aperture-collimated PBS as presented in
Chapter 2.1. Except Baumer et al. (21) these studies did not validate the dose calculation of
aperture-collimated PBS beams using a clinically commissioned TPS, a process that is required
for clinical implementation of apertures in PBS. While Baumer et al. performed validation of
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Raystation for lateral penumbra calculation of collimated PBS fields for varying energy and
depths, there was however no mention of the accuracy of penumbra calculation across varying
airgaps or range shifter thickness both of which are important parameters which can affect PBS
penumbra. The characterization and validation of the Raystation TPS for collimated PBS fields
across all relevant planning parameters which can affect lateral penumbra is needed for clinical
commissioning of aperture-collimated PBS beam delivery.
There were two primary aims of the work presented in this chapter. The first aim was to validate
Raystation’s MC dose calculation of lateral penumbra of aperture-collimated PBS beams
against film for all relevant parameters that affect lateral penumbra including depth, air gap
and range shifter thickness. In this study lateral penumbra was defined as 80% to 20% distance
of lateral dose fall-off. The second aim was to comprehensively characterize the reduction in
lateral penumbra between un-collimated and collimated PBS beam for different values of field
parameters. These aims were accomplished by validating the TPS-calculated penumbra values
for various PBS beams against film measurements.

3.2 Methods and materials
Measurements for this study were carried out on a fixed PBS beamline. SCCAPTC is equipped
with a proton delivery system (Proteus PLUS, Ion Beam Applications, Louvain-La-Neuve,
Belgium) with a cyclotron and energy selection system that generates proton beams ranging in
energy from 98.5 MeV to 228.5 MeV. Proton beams spots are Gaussian in shape with sigma
values at isocenter in air ranging approximately from 3.2 mm to 7.3 mm. For PBS treatment
fields delivered on the fixed beam-line, the PT system is commissioned to deliver a maximum
field size of 40 cm x 30 cm with a continuous range in water from 7.5 cm to 32.5 cm. For
shallow targets, at water-equivalent depths of less than 7.5 cm, acrylic range shifters are placed
at the end of the treatment snout for additional energy modulation. The Raystation TPS at
SCCAPTC has been commissioned to support a 4.0 cm or 7.5 cm (water equivalent thickness)
range shifter (13).
All PBS beams presented in this chapter were planned in Raystation v6.0. which supports two
dose calculation algorithms: PB dose engine (version 4.1) as well as the MC dose engine
(version 4.0) (11, 14, 45, 70).
Each PBS beam in this study was inversely optimized using the following MC dose calculation
settings: The dose calculation grid was set to 2 mm and each field was optimized using 10,000
ions/spot for 200 iterations. Optimization objectives were set to deliver 30.0 Gy (RBE) in 10
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fractions to the target volume which was the same across all plans and consisted of a rectangular
cuboid with dimensions of 10 cm x 10 cm at isocenter and varying length along the beam axis.
A max dose objective of 30.9 Gy (RBE) (i.e. 103% of RX) was placed on the target volume to
control hotspots and ensure dose uniformity. Each plan consisted of a single beam enface to
the phantom and was optimized to deliver uniform dose across the target. Other plan setting
settings used for optimization included an initial spot placement target margin of 0.6 cm with
energy and inter-spot spacing of 1 cm and 0.5 cm respectively. Following the completion of
200 iterations a final dose calculation was carried out using MC with a statistical uncertainty
of 0.5%.

Figure 3.1. (A) Lateral dose distribution of a single proton beam optimized to deliver uniform dose the target
(white contour) in a water phantom (blue volume) using a collimated PBS beam and 4.0 cm range shifter. (B)
Beams eye view illustrating the isocenter (orange crosshair), the PBS beam spot pattern (orange dots) shooting
through the aperture opening.

Each beam was copied, and brass apertures of 6.5 cm thickness were added within the TPS.
These aperture-collimated PBS beams were optimized using the same settings and dose
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calculation as the un-collimated beams. An illustration of one of the optimized PBS beams with
aperture is shown in Figure 3.1.
First, the characterization of PBS penumbra with depth was analyzed in the following manner:
Three separate treatment fields were optimized independently such that 95% of the target
volume was covered by 95% of the prescription dose (i.e. D95%=30 Gy (RBE)). These three
fields corresponded to three different range shifters: 0 cm (RS0), 4.0cm (RS40), and 7.5cm
(RS75). The physical thicknesses of the acrylic range shifters used at SCCAPTC are 3.5 cm
for RS40 and 6.5 cm for RS75.
Beam specific target volumes of field size 10x10 cm were created such that beams would have
the max residual range and SOBP width for each range shifter. This max residual range
corresponded to a proton beam energy of 221.9 MeV at nozzle entrance. This resulted in three
PBS plans with range and SOBP width as follows: (i) residual range 31 cm, SOBP width 23
cm for RS0, (ii) residual range 27 cm, SOBP width 23 cm for RS40, and (iii) residual range
23.5 cm, SOBP width 23 cm for RS75. Following optimization, dose files were exported and
analyzed in DoseLab (version 6.60, Mobius Medical Systems LP, Bellaire, TX, USA). Lateral
penumbra (80%-20% distance) was recorded at 2 cm intervals in depth along each target
volume for the un-collimated PBS beams.
Next, brass aperture collimators were applied in the TPS and each field was re-optimized using
MC dose calculation. Lateral penumbra of the collimated fields was then re-analyzed at 2 cm
intervals along each target volume. For fields using a range shifter, the central airgap between
phantom and rang shifter was set to 5 cm. Within the TPS air gap is defined as the distance
between the downstream range shifter surface and upstream phantom surface. In this
configuration, the distance from isocenter to the downstream surface of RS40 and RS75 was
20 cm. In the TPS, apertures are placed directly upstream from the range shifter. The
corresponding distance from isocenter to the downstream surface of the brass apertures was
20cm, 23.5cm and 26.5cm when using RS0, RS40 and RS75 respectively.
Next, TPS dose profiles were compared against film to validate the MC penumbra calculation
of aperture-collimated PBS beams. For this, all aperture-collimated PBS fields were transferred
to the MosaiqTM (Elekta, Sweden) radiation oncology information system. Non-divergent brass
aperture collimators were then milled in-house to mimic the aperture shape as planned in the
TPS. TPS measurement conditions were mimicked by placing Gafchromic EBT3 (Ashland,
NJ) films between slabs of solid water. The solid water slabs were placed on the treatment
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couch and each film was placed at specified depths. The treatment couch was then positioned
to align the solid water to treatment isocenter prior to beam delivery. Irradiated films were
scanned 24 hours after exposure using a flatbed scanner (Epson Expression 11000XL, Epson
America Inc., CA) and each pixel value was converted to optical density (OD). A nonirradiated film was also scanned in the same setup and subtracted from the irradiated films to
account for background. Finally, the OD files were converted to absolute dose value through a
calibration curve. Scanner resolution was set at 72 pixels per inch in the landscape orientation.
Digitized films were exported to DoseLab software where lateral penumbra values measured
with film were calculated and recorded.
Next, characterization of PBS penumbra and air gap between the range shifter and patient
surface was studied. For this, six beams of varying air gaps ranging from 5 - 30 cm in 5 cm
increments were generated using the RS40 and RS75 range shifters. Note that use of RS0 was
excluded because the air gap is undefined in this case. For each beam, the target volume
consisted of a 10x10x10 cm3 cube centered at depth of 15 cm inside a homogenous water
volume resulting in a beam of range 20 cm with SOBP width of 10 cm. Following optimization,
dose files were exported, and lateral penumbra was evaluated at depths of 7, 11, 15 and 19 cm
using DoseLab. Next, collimators were applied in the TPS and each field was recalculated
using the same dose and optimization as mentioned previously. The resulting lateral penumbra
values were analyzed at the same intervals as the uncollimated fields.

3.3 Results
Application of an aperture collimators to PBS beams resulted in a reduction in lateral penumbra
for all analyzed depths and across all three range shifter thicknesses.
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Figure 3.2. (A): TPS-calculated 2D dose distributions for a PBS beam with and without collimation in a water
phantom at 9 cm depth without range shifter and (B) 1D TPS-calculated dose profiles showing lateral penumbra
for a collimated (blue line) and un-collimated (red line) PBS beam. The white line in (A) indicates the location
of the profiles shown in (B).

Reduction in PBS lateral penumbra due to collimation decreased with increasing depth in water
and was most pronounced for shallow targets. Figure 3.2 shows the lateral penumbra for a PBS
beam in homogenous geometry with and without collimation as calculated by the TPS. The
reduction in penumbra with collimation versus without collimation is clearly observed. The
plots in Figure 3.3 show lateral penumbra as calculated by RS-MC and measured with film for
the collimated and un-collimated fields for varying depths and range shifter thicknesses. All
film-measured values of lateral penumbra matched RS-MC within +/- 1 mm (maximum
variation = 0.7 mm, mean variation = 0.3 mm, standard deviation = 0.2 mm).
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Figure 3.3. Calculated and measured lateral penumbra illustrating the comparison of penumbra with and without
collimation for three different beams with varying range shifter thicknesses, range, and SOBP width. (A): range
31 cm, SOBP width 23 cm, RS0. (B): range 27 cm, SOBP width 23 cm, RS40. (C): range 23.5 cm, SOBP width
23 cm, RS75.
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As can be seen in Figure 3.3, the magnitude of lateral penumbra increased approximately
linearly with depth for all three range shifters with and without aperture collimation. With
varying range shifter thickness and same SOBP width, excellent agreement was observed
between the penumbra values calculated with RS-MC and those measured with film.
A scatter plot of lateral penumbra reduction (i.e. un-collimated minus collimated penumbra)
vs. depth is presented in Figure 3.4. Linear regression curves are overlaid onto the scatter plots
to illustrate the trend and slope of penumbra variation with depth.

48

Figure 3.4. Comparison of TPS-calculated lateral penumbra reduction with and without aperture collimation for
the three different range shifter thicknesses.

As shown in Figure 3.4, the linear slope of penumbra reduction is -0.10 mm/cm for RS0 and 0.16 mm/cm for RS40 and RS75. At 2 cm (i.e. the shallowest depth), penumbra reduction was
2.7 mm, 3.7 mm and 4.2 mm for RS0, RS45 and RS75 respectively. Penumbra reduction was
reduced to 1 mm at a depth of approximately 23 cm for RS0 and 20 cm for RS40 and RS75.
Figure 3.5 shows the lateral penumbra values for air gaps ranging in value from 5 cm to 30 cm
(in 5 cm increments) calculated by RS-MC at four depths for the RS40 and RS75 range shifters.
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Figure 3.5. Variation of TPS-calculated lateral penumbra (y-axis) vs. air gap (x-axis) at various depths for
RS40 - un-collimated (A), RS40 - collimated (B), RS75 – un-collimated (C) and RS75 – collimated (D).

As shown in Figure 3.5 lateral penumbra increases approximately linearly with both depth and
air gap for both RS40 and RS75. For RS40 without collimation, the lateral penumbra increased
from 7 mm (depth 7 cm, air gap 5 cm) to 13 mm (depth 19 cm, air gap 30 cm). With collimation,
the penumbra increased from 5.1 mm (depth 7 cm, air gap 5 cm) to 12.6 mm (depth 19 cm, air
gap 30 cm). For RS75 without collimation, the lateral penumbra increased from 7.5 mm (depth
7 cm, air gap 5 cm) to 14.9 mm (depth 19 cm, air gap 30 cm). With collimation, the lateral
penumbra increased from 5.7 mm (depth 7 cm, air gap 5 cm) to 14.8 mm (depth 19 cm, air gap
30 cm). All TPS-calculated lateral penumbra values of PBS-collimated fields matches film
measurements within +/- 1 mm (max variation = 0.9 mm, mean variation = 0.3 mm, standard
deviation = 0.2) across all combinations of air gap and depth.
Applying a 2nd order polynomial surface fit to the penumbra reduction (PR) as a function of
depth and airgap results in the following relationship:
𝑃𝑅

𝐶

𝐶 𝐴𝐺

𝐶𝑑

𝐶 𝐴𝐺 𝑑

𝐶 𝐴𝐺

𝐶𝑑

(Equation 1)
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where d is the depth in water and AG is the airgap between the phantom surface and range
shifter. The fitting parameters, 𝐶

𝐶 , for Equation 1 are shown in Table 3.1 for RS40 and

RS75.

𝐶
𝐶
𝐶
𝐶
𝐶
𝐶

𝑅𝑆40
2.39
5.53 𝑥 10
4.49 𝑥 10
2.16 𝑥 10
1.07 𝑥 10
4.30 𝑥 10

𝑅𝑆75
2.07
6.95 𝑥 10
2.73 𝑥 10
2.17 𝑥 10
9.29 𝑥 10
4.66 𝑥 10

Table 3.1. Fitting parameters for a 2nd order polynomial surface fit of penumbra reduction as a function of depth
and airgap.

Figure 3.6 shows 2D contour plots Equation 1 for the RS40 and RS75 range shifter penumbra
data illustrating penumbra reduction as a function of air gap and depth.
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Figure 3.6. 2-D contour plot illustrating TPS-calculated lateral penumbra reduction as function of airgap and
depth for RS40 (A) and RS75 (B).

Figure 3.6 shows that penumbra reduction is largest at shallow depths and small air gaps when
using both RS40 and RS75. Penumbra reduction decreased as both the depth and air gap are
increased.
Next, a clinical example patient is presented here to compare penumbra reduction between
collimated and un-collimated PBS treatment fields. The field arrangement for this treatment
plan is shown in Figure 3.7.
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Figure 3.7. 3D view of the beam arrangement used in the clinical example
on a test patient.

Figure 3.8 shows axial dose distributions of the un-collimated PBS plan (A), collimated PBS
plan (B), dose difference (C) and line dose profile across the two treatment plans (D).
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Figure 3.8. Axial dose distributions for the un-collimated PBS plan (A), collimated PBS plan (B) dose
difference (C) and line dose profile across the two treatment plans (D).

The line dose profiles in Figure 3.8 were analyzed in DoseLab and had an average (right-left)
lateral penumbra of 1.25 cm for the un-collimated PBS plan and 1.02 cm for the aperturecollimated plan. The resulting average reduction in penumbra along the right and left side of
the patient target in the axial view as shown in Figure 3.8 is therefore 2.3 mm. This value agrees
well with Equation 1 which yields a lateral penumbra reduction calculation of 1.9 mm when
using the fitting parameters shown in Table 3.1, an airgap of 5 cm and depth of 6 cm which is
the approximate depth the target (red contour) shown in Figure 3.8.
Figure 3.9 shows the corresponding DVH for the collimated and un-collimated PBS plans
presented in Figure 3.8.
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Figure 3.9. Dose volume histogram for the PTV, optic nerve, chiasm, pituitary and hippocampus for PBS plans
optimized with and without aperture collimation.

As can be seen in Figure 3.9, target dose is maintained while dose to several nearby OARs is
reduced. Table 3.2 shows the corresponding dose statistics for the PTV and multiple affected
OARs.
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Dose [cGy]
Plan

ROI

ROI vol. [cm3]

D99

Average

D1

PBS - Collimated

Chiasm

0.29

629

3063

5050

PBS - Un-collimated

Chiasm

0.29

2124

3922

5049

PBS - Collimated

Hippocampus R

1.27

85

1440

4908

PBS - Un-collimated

Hippocampus R

1.27

608

2261

4924

PBS - Collimated

Optic Nerve L

0.51

4

47

945

PBS - Un-collimated

Optic Nerve L

0.51

5

209

2647

PBS - Collimated

Optic Nerve R

0.51

2

54

947

PBS - Un-collimated

Optic Nerve R

0.51

4

239

2675

PBS - Collimated

Pituitary

0.49

265

1047

2926

PBS - Un-collimated

Pituitary

0.49

1362

2423

3764

PBS - Collimated

PTV

59.21

4948

5141

5249

PBS - Un-collimated

PTV

59.21

4967

5138

5252

Table 3.2. Dose statistics for the PTV and multiple OARs showing various dose statistics for collimated and uncollimated PBS plans.

3.4 Discussion
In this study, the variation in lateral penumbra as a function of depth, air gap, and range shifter
thickness for collimated PBS beams using the Raystation TPS was quantified. The results of
this study showed that air gap, depth, and range shifter thickness affect the reduction in the
lateral penumbra that can be achieved through aperture collimation.
Lateral penumbra reduction through aperture collimation diminished with depth. This was
primarily due to increased proton scatter as beam spots traversed the medium. At increased
depths, penumbra broadening of collimated beams along field edges due to scattering within
the patient approached the lateral penumbra of un-collimated PBS beams. Therefore, use of
collimation for PBS fields may not be beneficial for deep-seated tumors such as prostate or
other abdominal treatment sites. The lateral penumbra reduction with collimation was
negligible (at less than 1 mm) at large depths greater than approximately 20 cm. It is also
important to note that penumbra reduction through aperture collimation is dependent on PBS
spot size. This means that PBS systems that have larger spot sizes may benefit from aperture
PBS more so than systems with smaller spot sizes.
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In this work it was found that for varying depth, airgap and range shifter thickness, the RS-MC
dose algorithm calculated the lateral penumbra accurately. For the collimated fields across
multiple depths and range shifter thicknesses, MC calculation matched film measurements of
lateral penumbra within +/- 1 mm. Other studies have also demonstrated good agreement
between RS-MC and measurements of un-collimated fields (11, 71). Saini et al. validated the
Raystation MC dose calculation against film measurements in a heterogeneous environment
using an Alderson–Rando phantom and found that 6 out of 7 lateral dose profile planes had
gamma pass rates greater than 90% using a dose difference of 3%(global) and a distance to
agreement (DTA) of 3mm and low-dose threshold of 10% (11). In a similar study, Sorriaux et
al. found a 95.9% (2%(local)/2mm gamma index criteria) agreement between Raystation MC
and measurements made with an ion chamber array in an anthropomorphic phantom (71).
This chapter has also presented a treatment plan generated in Raystation using a patient CT in
which un-collimated and collimated PBS beams were optimized and the penumbra across the
target volume was compared. Baumer et al. has carried out a similar study using Raystation in
which a collimated PBS treatment plan was compared against a US plan for the irradiation of
an ocular orbit (21). Comparisons of the order of range shifter and aperture and the impact on
lateral penumbra were also studied by Baumer et al. The work presented in this chapter differs
with Baumer et al. in that the difference in penumbra with and without aperture collimation
across multiple planning parameters was investigated. Furthermore, this work has derived an
analytical formula to predict the lateral penumbra based on depth of target and air gap. This
analytical formula can be used by clinicians during planning to decide whether aperture
collimation would have dosimetric benefit for patients who are to receive PBS treatments.
The analytical formula had the following limitations. First, it was derived in homogeneous
media and may not account for scatter caused by heterogeneities found within patient anatomy.
This limitation could cause discrepancies based on differing scatter properties between
homogeneous and heterogeneous media. Second, the formula was derived for properties of
single beams impinging on a rectangular target. Although this approximation is common in
routine radiotherapy quality assurance, patients often receive multiple beams impinging on
rounded surfaces. As a test of the robustness of the model against these specific limitations, a
clinical patient example in which three fields targeted a tumor volume located in the brain of a
heterogeneous patient CT was selected. Even with these potential limitations, the penumbra
values predicted by Equation 1 agreed well with the TPS-calculated penumbra of the clinical
patient example (to within 0.5 mm). Finally, the analytical formula presented in this study was
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derived using spot sigma values ranging from 3.2 mm to 7.3 mm. Therefore, Equation 1 along
with the fitting parameters in Table 3.1 may not be valid for proton therapy systems with spot
sizes drastically different than that used in this work. Future studies may investigate the effects
of adding additional terms to the analytical penumbra model that consider heterogeneities
within the patient as well as varying PBS spot sizes.
Although use of apertures for PBS fields allows for some dosimetric advantages for certain
patients/disease sites via sharper penumbras, there are various limitations to consider for
clinical implementation. Firstly, the added duration to the treatment planning timeline needed
for utilizing apertures for PBS fields should be considered. Milling of field apertures must take
place prior to QA/treatment, takes time and can add to the cost of treatment. Additional patient
QA tests should also be performed prior to treatment to ensure that the milled aperture shapes
match the TPS within an appropriate tolerance. Use of apertures can also add to the treatment
time as they must be switched out in between beam deliveries. Finally, various studies have
investigated increased out-of-field dose due to neutron contamination as well as increased dose
averaged LET within the field when using apertures with PBS fields (72-74). It is therefore
important for clinicians to assess these timeline and radiation protection considerations prior
to clinical implementation of PBS apertures.

3.5 Conclusion
In conclusion, the findings presented in this chapter show that apertures can measurably
sharpen the lateral penumbra of PBS fields. The lateral penumbra of collimated PBS beams
varied as a function of depth, airgap and range shifter thickness. The results demonstrated that
the use of apertures for PBS treatments is most beneficial for shallow targets while maintaining
small air gaps. At approximately 20 cm depth, the benefit of using an aperture diminished with
penumbra reduction reducing to less than 1 mm. Furthermore, it was found that the Raystation
MC dose engine calculated lateral penumbra with sufficient accuracy for clinical use. PBS
penumbra reduction through collimation was also demonstrated on a clinical CT scan for a
brain case and the corresponding DVH and dose statistics for the target and affected OARs
were presented. Finally, an analytic equation which can predict lateral penumbra reduction
between collimated and un-collimated PBS treatments as a function of target depth and airgap
was introduced. This analytic equation was able to predict the penumbra reduction to within
0.5 mm using a clinical CT scan.
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CHAPTER 4: VALIDATION AND CLINICAL
IMPLEMENTATION OF SEATED POSITION FOR
PROTON PENCIL BEAM SCANNING IN A
COMMERCIAL TPS
The results presented in this chapter have been published in the European Journal of Medical
Physics:

Maes D, Janson M, Regmi R, Egan A, Rosenfeld A, Bloch C, et al. Validation and practical
implementation of seated position radiotherapy in a commercial TPS for proton therapy.
Physica Medica. 2020;80:175-85.
Author Contributions:
This project was conceived by JS and DM. Project was led by DM and JS. DM and JS
performed measurements and data collection with assistance from ZN. Figures and text were
composed by DM and JS in consultation with MJ, RR, AE, AR, CB and TW.

4.1 Introduction
Recently the Raystation TPS (version 9B) has added new 6D couch features that allow for
radiotherapy treatments in the seated position. In this chapter, the aim will be to validate and
provide readers with a guideline for the practical implementation of these new features for
chair-based treatments. Chair-based treatments have been shown to be a cost-effective solution
for particle therapy centers that have partial or fixed PBS beamlines (34, 75-78). Over the past
5 years, more than 300 ocular patients have been treated in the seated position using a treatment
chair at SCCAPTC. These patients were treated using uniform scanning with treatment
planning carried out using the XiO TPS (Elekta Instrument AB, Stockholm, Sweden). Although
SCCAPTC has adopted Raystation as its primary TPS due to its modern design, functionality,
and ease of use, treatments in the seated position had to be planned in XiO due to a lack of a
chair feature in previous versions of Raystation. This resulted in SCCAPTC spending extra
resources in supporting an additional TPS for the sole purpose of chair-based treatments. The
new 6D couch features have the potential for substantial savings to proton centers that are
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similar to SCCAPTC by providing an avenue to move to a single TPS for all proton treatments.
Additionally, centers with fixed beamlines have the potential to expand their treatment delivery
capabilities by implementing chair-based treatments.
Most current commercial TPSs offer only a flat couch top as a patient support device for
planning and treatment positions are limited to prone or supine patient orientations. Clinicians
can modify beam direction through a combination of gantry angle and/or couch rotation. In the
Raystation TPS, existing planning features are supplemented with several 6D couch features:
(i) an option to have patient support to be either a flat treatment couch or a chair, (ii) an
additional patient treatment orientation of ‘sitting’, and (iii) allowing patient support devices
to have additional degrees of freedom in the form of pitch and roll. In the sitting orientation,
the Raystation TPS rotates the image volume such that a head-first-supine (HFS) or feet-firstsupine (FFS) scan can be planned with the superior-inferior axis parallel to the IEC treatment
room z-axis. These additional features can be configured to have a streamlined workflow for
chair-based proton therapy delivery. Along with other advanced capabilities offered in the
Raystation TPS, particle therapy centers can modernize their chair-based treatments.
The overall aims of this chapter are to validate the Raystation TPS implementation of the 6D
couch features and provide an implementation strategy for chair-based treatments in the
following 2 steps:
1) The implementation of extra degrees of freedom for couch motion (pitch and roll) were
verified.
2) Practical implementation of the 6D couch features for treatment in the seated position
in a chair is described. An end-to-end test using an anthropomorphic phantom was
carried out to fully validate the workflow of treatment.

4.2 Materials and methods
4.2.1 Relevant equipment and software
SCCAPTC is a four-room proton therapy facility with capabilities to treat patients using PBS
and US. Patients are simulated with a GE Optima 580W CT scanner (GE Healthcare,
Waukesha, WI). MOSAIQ (version 2.64) (Elekta Medical System, Sweden) oncology
information system is used to monitor and schedule patient treatments. For the work presented
in this chapter, treatment planning was performed with Raystation (version 9B) TPS. Couch
rotations were verified through orthogonal x-ray images using the MIMI phantom (Standard
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Imaging, Middleton, WI). Orthogonal x-ray images were acquired and analyzed through the
Medcom Verisuite Imaging System (Ion Beam Applications, Louvain-Neuve, Belgium).
Patient-specific 2D dosimetric measurements were acquired through Gafchromic EBT3 film
(Ashland Advanced Materials, Wayne, NJ) and MatriXX PT ionization chamber array (IBA
Dosimetry, Schwarzenbruck, Germany). 2D dosimetric analysis of the film and ion chamber
array measurements were performed in the OmniPro I’mRT (Ion Beam Applications, LouvainNeuve, Belgium) software.

4.2.2 Validation of 6D couch features
All treatment couches at SCCAPTC adhere to translation and rotation conventions outlined in
the IEC standard 61217, which specifies the direction as well as the order of radiotherapy
treatment couch rotations. To verify that simulated rotations (pitch, roll, and yaw) in RS were
consistent with IEC61712 several treatment plans with varied couch orientations were
generated and translated through Mosaiq to the IBA couch positioning system. These couch
rotations were applied and then measured with a digital level to ensure they were correct. For
a subset of treatment beams, the rotations were also verified by comparing TPS-generated
digitally reconstructed radiographs (DRRs) of a previously-scanned MIMI phantom (Figure
4.1) to orthogonal planar x-rays images. For the acquisition of x-ray images, the MIMI phantom
was aligned to isocenter and the associated couch rotations for each beam was applied. The
DRRs and x-ray images were overlaid and compared against each other in the Verisuite
imaging software.
Additional dosimetric tests were performed to ensure that RS correctly orients treatment beams
onto the patient image for various patient position settings and couch rotations. For these tests
a head phantom was scanned with two different orientations (HFS and FFS). Twelve test beams
with different couch rotations were created for the two scanning orientations (Table 4.1). A
TPS screenshot of beams with several pitch angles is shown in Figure 4.2. Treatment beams
consisted of a single layer PBS beam with an asymmetric field shape to enable easy verification
of orientation. Figure 4.2 (b) shows the BEV of three fields with various pitch/roll
combinations. All 12 beams were mapped onto a phantom geometry designed to model the
MatriXX PT ion chamber array using the QA plan generation tools in Raystation. Because the
intent is to test the correct orientation of the beam when couch rotations are applied, couch
rotations and gantry angles were all retained in the QA geometry within the TPS. Beams were
then transferred to Mosaiq for delivery and measurements acquired with the MatriXX PT which
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was placed on a 360-degree rotational mounting device affixed to the treatment couch as shown
in Figure 4.3. Use of this mounting device allowed for the application of rotations to the
MatriXX PT in the treatment room that mimicked 6D couch rotations simulated in the TPS.
Measured planes were first visually compared to the TPS BEV dose to ensure correctness of
beam orientations and shapes. Measured planes were also compared to TPS-generated planes
for gamma index analysis using a DTA of 3 mm and dose difference of 3%.

Figure 4.1. Picture of the MIMI phantom used for verification of couch rotations (A)
and screen shots from the TPS of the phantom CT in the axial (B), sagittal (C) and
coronal (D) orientations.
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Table 4.1. Table showing the test beams used with various combinations of scanning orientation, treatment
orientation and 6D couch rotations.

Figure 4.2. (a) 3D representation of the patient along with beams of different pitch angles with the patient in the
seated position. (b) BEV corresponding to three beams with pitch and roll rotations for a phantom to be treated
in the seated position.
.
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Figure 4.3. Screen shot from the TPS showing phantom rotations in a QA plan (left) and corresponding
measurement with an ion chamber with applied rotation to simulate chair or tabletop rotation (right).

4.2.3 Treatment chair implementation
At SCCAPTC, seated treatments are performed utilizing a commercial treatment chair (RT4534, Qfix, Avondale, Pennsylvania). The patient’s head rests against a curved neck support
frame and is secured by a thermoplastic mask. The back insert is battery-powered and can be
adjusted to account for a patient’s height. The chair is compatible with standard BoS masks
that can be used to immobilize the patient’s head. There are adjustable arm and foot supports
that can be set to a patient’s comfort. The chair mounts on a fixed robotic base that allows for
pitch, roll, and yaw corrections, which can be applied during image guided radiation therapy
(IGRT) alignment. The robotic base allows for the chair to be swapped with a traditional couch
top for treatments in supine or prone positions.
Patient support type in the TPS beam model was changed to “Chair” to accurately simulate the
patient in the sitting position. The TPS beam model also has options to define relevant pitch
and roll limits which can be set accordingly. If using the same beamline for both chair and a
traditional flat top couch, two beam models for the same beam could be commissioned in
Raystation: one with Chair as a patient support type and the other with Table as a support
device. Finally, the chair has a fixed recline of 20 degrees with a back support insert. This
treatment chair recline is implemented in Raystation through a +20-degree table-top pitch with
the patient position set to sitting for a HFS scan. It is important to note however that the pitch
angle must be set to zero in the MOSAIQ software when translating plans since the 20-degree
pitch is an implicit offset in the chair system.
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In addition to the aforementioned TPS settings, chair settings also need to be defined in the
oncology information system so that DICOM plans with chair tags can be imported. In
MOSAIQ version 2.64, chair parameters can be included in the Machine Characterization
Editor. With this version of Mosaiq the two required tags are Chair Pitch Angle and Chair Roll
Angle. The addition of these two tags enables the chair pitch and roll parameters to appear in
the treatment setup and field definitions within MOSAIQ.

4.2.4 End-to-end testing
End-to-end testing was carried out using an anthropomorphic head phantom. The process of
phantom CT simulation and treatment delivery was designed to follow the actual clinical
protocol at SCCAPTC. The head phantom was simulated HFS using the ocular CT protocol.
Phantom immobilization was conducted using a thermoplastic mask and mold care which were
affixed to the neck support frame as shown in Figure 4.4. Radiopaque BBs were placed on the
mask for localization purposes and the phantom CT was imported into the TPS. A pseudo target
in the ocular region was created and treatment planning was performed using US proton beam
delivery with two beams: AP and RLAT. For the uniform scanning beamline at SCCAPTC,
the proton beam is shaped distally by a wax compensator and laterally by a brass aperture.
Additional details of a uniform scanning beamline are described in Nichiporov et al (79). For
treatment planning, beam-specific apertures and compensators were conformed to the target
volume to ensure optimal dose conformity. The dose to the target volume was 50 Gy in 5
fractions. Phantom dose distributions in three orthogonal planes and associated beam
arrangements are shown in Figure 4.5. The treatment plan, CT images, and structure set were
then transferred to MOSAIQ for beam delivery. As previously mentioned, the couch pitch
value transfers as 20 degrees from the TPS to MOSAIQ and was manually changed to zero to
account for the chair’s physical recline. For this work, relative dosimetry of the designed plan
was considered adequate for assessing field shape and orientation.
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Figure 4.4. Pictures of the anthropomorphic head phantom setup on the CT table with neck support and
thermoplastic mask (right and middle) and in-room setup using the treatment chair (right).

4.2.5 Phantom patient-specific quality assurance
Prior to end-to-end testing, the phantom plan was mapped to a solid water phantom used for
patient-specific QA. Dose profile measurements were then obtained using Gafchromic film
sandwiched between proton-compatible solid water slabs. Film-measured and TPS-calculated
dose profiles were compared with gamma index analysis using 3% /3 mm pass/fail criteria.

4.2.6 Phantom treatment simulation
The CT images along with associated structure set and treatment plan was then transferred to
Verisuite for IGRT. The phantom and associated immobilization accessories were immobilized
in the treatment chair and set up to the isocenter using the BBs which were placed during
simulation. Orthogonal x-ray images were acquired at each chair location and compared to the
DRRs for treatment setup localization. Appropriate shifts were applied until the phantom was
aligned within 1 mm in A-P, S-I, and R-L directions. Once aligned, BEV x-ray images were
obtained with beam-specific apertures in place. These BEV images were compared to the
corresponding DRRs obtained from the TPS to ensure a visual match between the simulated
and treatment field.
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Figure 4.5. Screenshot from the TPS showing the treatment plan generated from on the anthropomorphic head
phantom as the part of end-to-end testing of the Raystation 6D couch features.

4.3 Results
4.3.1 Validation of 6D couch features
Pitch, roll, and yaw rotations in Raystation were consistent with IEC standards which are
illustrated in Figure 4.6. The direction of rotation and magnitude in the TPS was consistent
with the physical couch in the treatment room. Figure 4.7 shows the orthogonal DRRs and xray images of the MIMI phantom for select treatment fields. The DRRs were found to have an
acceptable agreement with planar x-rays based on visual inspection. The 3%/3 mm gamma
index analysis between measured and calculated dose profiles for a subset of beams is shown
in Figure 4.8. The maximum, minimum, and average pass rates for all fields were 99.6%,
95.8%, and 98.5% respectively. The visual inspection of field shape and orientation for all
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beams agreed between measured and delivered dose profiles. The workflow within the
Raystation TPS was successful in reproducing correct field shape and orientation as requested
by the planner.

Figure 4.6. Pitch and roll axis of rotation and direction were compared between Raystation and the actual
treatment couch across multiple couch rotations. The Raystation implementation is consistent with IEC 61217
standard. A1 and A2 illustrate pitch and roll definitions for couch rotations at either 0 and 180 degrees. B1 and
B2 show pitch and roll definitions for couch rotation at either 90 and 270 degrees.
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Figure 4.7. Comparison of TPS DRRs against planar X-ray images for various combinations of, couch rotations
(T), pitch (P), and roll (R). Images were acquired at gantry angle (G) 90. All angles are in degrees.
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Figure 4.8. 2-D Gamma (3%/3mm criteria) index analysis for a subset of beams given in Table 4.1.

4.3.2 Phantom patient-specific quality assurance
Aperture overlays were obtained by printing TPS-generated aperture profiles to actual physical
scale. Brass apertures were milled in-house and then positioned on top of the aperture overlay
printout to ensure correctness of the field opening within ± 1mm.
The treatment beams were also delivered to a solid water phantom to be measured individually
by Gafchromic film sandwiched between slices. For this irradiation, the field parameters
(couch and gantry angles) were positioned to have en-face orientation for irradiation.
Measurement conditions such as isocenter location and film depth corresponded to mapped
phantom conditions in the TPS. Each measured beam was compared to the corresponding TPSgenerated 2D dose profile. The resulting gamma index analysis for these fields had pass rates
of 94.3% and 95.6% for RLAT and AP fields respectively following patient-specific QA
measurements.
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4.3.3 Phantom treatment simulation
The phantom treatment was performed in the same fashion as actual treatments for chair-based
patients SCCAPTC to ensure consistency with current clinical practice. A radiation therapist
assisted in the alignment of the phantom to its treatment position using IGRT. The phantom
was successfully imaged and subsequently aligned at both chair positions with a residual error
less than 1 mm. The phantom anatomy as viewed on BEV IGRT images in Verisuite matched
visually with a TPS-generated BEV DRR. Both the beams were successfully delivered to the
phantom.

4.4 Discussion
Today there are numerous particle therapy centers treating with chair-based radiotherapy in the
seated position. Chair-based treatments may also be needed for some patients who cannot
tolerate lying flat either due to cancer or other underlying condition (23, 32, 80). This work has
verified that Raystation’s implementation of the pitch, roll, and yaw is consistent with IEC
standard 61217 and matches the physical couch positioning system as measured in the
treatment room. Furthermore, it was verified that the TPS-generated DRRs matched the planar
x-ray images that were acquired with a phantom positioned on the treatment table. All the
treatment couch pitch, roll and yaw rotations were applied automatically through a robotic
positioning system. Additional dosimetric validation was performed using 12 fields with varied
scanning and couch rotation settings. The gamma index passing rate for all beams was greater
than 95% using 3%/3mm pass/fail criteria. This verified that the newly added 6D couch
features can be successfully integrated into a clinical workflow for support of treatments in a
seated position. In the end-to-end test, the viability of chair-based treatments was demonstrated
through an ocular case example in relative dosimetry mode. It is important to note however
that additional considerations for absolute dosimetry of small fields (~2 cm) that are
encountered in ocular-based treatments were not considered in this work and users should
validate their small field dosimetry if this workflow is to be used for treating small targets.
The work presented in this chapter has the potential to help particle therapy centers with fixed
beamlines. The methods described in this work can serve as a template for other centers
attempting to implement chair-based workflows using the 6D couch features with Raystation
or other treatment planning systems. Raystation’s 6D couch features also provide additional
flexibility by allowing users to change chair-back angles during the planning process allowing
for a single beam model for treatment chairs that may have variable recline angles.
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4.5 Conclusions
The newly added 6D couch features in Raystation were found to have implementation that is
consistent with IEC 61712 standards. The functionality of these features can be easily
combined to enable a seamless workflow for treatments in the seated position. Validation of
this treatment chair in the Raystation TPS will allow for treatment of additional disease sites
when using a fixed PBS beamline.
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CHAPTER 5: MONTE CARLO VS. PENCIL BEAMBASED PLANNING FOR LUNG CANCER
The results presented in this chapter have been published in the Journal of Translational Lung
Cancer Research:

1) Saini J, Traneus E, Maes D, Regmi R, Bowen SR, Bloch C, et al. Advanced Proton
Beam Dosimetry Part I: review and performance evaluation of dose calculation
algorithms. Transl Lung Cancer Res. 2018;7(2):171-9.
2) Maes D, Saini J, Zeng J, Rengan R, Wong T, Bowen SR. Advanced proton beam
dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer.
Translational lung cancer research. 2018;7(2):114-21.
Author Contributions:
This project was led and organized by DM, JS and SB. Treatment plan reoptimization and data
analysis was carried out by DM and SB. Figures and text in this chapter were composed by
DM and SB in consultation with TW, RR, JZ and JS.

5.1 Introduction
PBS proton therapy has been used to effectively treat a multitude of oncologic disease sites
(12). Lung cancer, particularly in the setting of locally advanced disease, is commonly treated
with PBS. For treatment planning of this disease site, many technical challenges must be
considered including respiratory motion-induced interplay effects (81, 82) as well as tissue
density heterogeneities and overrides within and proximal to the target volume (83).
Traditionally, the standard dose calculation technique for this type of anatomical site has relied
on analytical PB dose calculation algorithms (84) as this has historically been the only available
solution across commercial proton treatment planning platforms. Many of these analytical dose
algorithms are based on the works of Hong et al. (45) and Schaffner et al. (46). Analytical
algorithms such as PB algorithms allow for fast and efficient computation but are less accurate
for proton beam dose calculation especially in the presence heterogeneous tissue interfaces (41)
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commonly found within patient anatomy. Furthermore, variations in dosimetry from differing
proton therapy dose calculation algorithms can have future effects on tumor control probability
and normal tissue complication rates (85).
Recently, Raysearch Laboratories has incorporated a commercial MC dose calculation
algorithm which was first introduced in the Raystation version 6.0 TPS (13). The inclusion of
MC within a TPS moves beyond in-house solutions (36) and facilitates clinical implementation
of increased accuracy in dose calculation for complex disease sites such as lung lesions. Fast
MC dose calculation within Raystation is facilitated through the use of multiple variance
reduction techniques including use of a continuous slowing down approximation for energy
loss of heavy secondary particles as well as the exclusion of secondary delta electron transport
(70).
Many previous studies on MC dose calculation for small proton fields (40), as well as
comparisons of PB vs MC, have been limited to phantoms studies (11, 38, 49, 86). While these
investigators have characterized a range of dose calculation errors under different conditions
they did not explicitly evaluate dosimetric effects on clinical patient data. Increased
understanding of MC dose calculation and the impact of optimization on clinical treatment
planning of lung lesions relative to PB dose calculation and optimization could reveal important
tradeoffs in plan quality and establish realistic goals for proton therapy dosimetry.
In this chapter, lung cancer treatment planning between PB and MC dose engines in clinical
PBS plans was investigated through a retrospective analysis of a select patient cohort treated
at SCCAPTC. This retrospective analysis of 10 lung cancer addresses the following 3 topics:
(1) differences in dose to targets and OARs when PB-optimized treatment plans are recalculated with MC, (2) difference in target coverage/uniformity and dose to OARs between
PB-optimized and MC-optimized plans and (3) difference in robustness to setup and range
uncertainties between perturbed doses of PB-optimized and MC-optimized treatment plans.

5.2 Methods
5.2.1 Patient cohort
With Institutional Review Board approval, planning data from 10 previously-treated lung
cancer patients receiving PBS to the thorax were reviewed and analyzed. Five patients
presented with either small or non-small cell lung cancer and were treated using various
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combinations of treatment modalities including adjuvant radiation and concurrent
chemoradiation. The remaining five patients were enrolled onto a clinical trial (NCT02773238)
that employed a functional lung avoidance optimization technique (87) with the strict eligibility
criteria. Patients on this trial were treated to at least 60 Gy (RBE) in 30 fractions. Across all 10
patients, tumor volumes ranged from 81 cc to 637 cc with a median of 261 cc. All tumor
volumes contained areas of heterogeneity characterized by lung-tissue interface.

5.2.2 Simulation technique
Patient CT simulation was performed utilizing a free-breathing acquisition of 4D computed
tomographic (4DCT) imaging using a GE Optima CT580 scanner. Patient CT settings included
a tube potential setting of 120 kVp and 2.5 mm slice thickness. Respiratory traces were
recorded by the AZ 733V Respiratory Gating SystemTM (Anzai Medical Co. Ltd., Tokyo,
Japan) system which employed a pressure sensor belt. 4DCT data were binned into 10 equallyspaced phases across the patient breathing cycle. The total vector target motion was evaluated
to be less than 1.0 cm across all patients. This total vector motion of 1.0 cm did not require
further motion mitigation strategies such as abdominal compression per SCCAPTC clinical
guidelines. Instead, a motion-encompassing treatment strategy was employed that included
volumetric rescanning (88, 89) of PBS beams to dampen the interplay between scanning
magnet motion and tumor motion frequencies.

5.2.3 Treatment planning and optimization parameters
DICOM CT data were imported into the Raystation TPS and PBS beams were optimized for
dose calculation on the 4DCT phase-averaged image. Treatment plans utilized 1-2 treatment
fields (2-4 fields with 2x volumetric rescanning) and were planned using single-field robust
optimization to maintain target coverage under perturbed conditions of 3% range and 3 mm
setup uncertainty. Prescriptions consisted of proton beam therapy regimens with curative
intent, ranging from 60-66.6 Gy (RBE) in 1.8-2.0 Gy (RBE) per fraction and using an average
RBE of 1.1. Additional beam computation settings used for PB and MC optimization included
default energy layer spacing and spot spacing parameters set to 1.0 cm. A lateral margin of up
to 1.0 cm was used for spot placement around the target and all optimizations were carried out
on a 2 mm calculation grid for 200 iterations using sampling history of 10,000 ions/spot. Upon
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completion of optimization, final MC dose was computed using a sufficient number of ions to
yield 0.5% statistical uncertainty across the tumor volume. All treatment plans were normalized
such that the prescribed dose covered 95% of the planning target volumes.

5.2.4 Dosimetric and statistical analysis
PBS single field optimization was first carried out using PB dose calculation to achieve clinical
goals for target coverage and dose to OARs in compliance with the current standard of care at
SCCAPTC. PB-optimized treatment plans were then re-calculated with MC without
modification to layer spacing, spot spacing or spot intensity distributions. Finally, field-specific
energy layers, spot positions and spot intensities were reset and re-optimized using MC while
maintaining the same optimization parameters. Dose differences between the PB-optimized
(PBopt), MC-recalculated (MCrecalc) and MC-optimized (MCopt) treatment plans were
recorded for the following plan metrics: CTV V95, CTV homogeneity index (HI), total lung
V20, total lung VRX (relative volume of lung receiving the prescribed dose or higher), and
global maximum dose. Pairwise differences in planned dose and dose-volume parameters
between PBopt, MCrecalc, and MCopt were analyzed using a non-parametric Friedman test.

Perturbed dose distributions were generated in Raystation for the evaluation of plan robustness
with regard to setup and range uncertainty. Perturbation scenarios were generated by scaling
CT density by +/- 3% to evaluate the range uncertainty of PBS beams and beam isocenters
were shifted by +/- 3mm in the x, y and z directions to evaluate patient positioning setup
uncertainty. For simplicity, this study considered the following two dose perturbation
scenarios: (+3%, x+3mm, y+3mm, z+3mm) and (-3%, x-3mm, y-3mm, z-3mm). Perturbed
doses were generated for MC-recalculated and MC-optimized treatment beams and pairwise
differences between MC-recalculated and MC-optimized perturbed dose distributions were
evaluated using a non-parametric Wilcoxon sign-rank test.

5.3 Results
Figure Figure 5.1 illustrates isodose distributions overlaid on a patient planning CT using three
planned dose conditions: PBopt (A), MCrecalc (B) and MCopt (C). As can be seen in Figure
5.1, tissue inhomogeneities within the patient anatomy increase the spread in range from the
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posterior beam direction in the MCrecalc dose distribution (B) which causes a reduction in
proton range. Furthermore, dose shadowing on proton beam paths beyond bone is more
pronounced in MCrecalc (B) compared to PBopt (A). This under-ranging is corrected in the
MCopt plan (C), though the distal edge features more lateral dose inhomogeneity than the
PBopt plan (A). Figure 5.1 (D) shows a DVH for the CTV (green) and lung (blue). There is a
noticeable drop in dose coverage to the CTV in the MCrecalc plan (dotted line). This dose
coverage to the CTV is recovered in the MCopt plan (dashed line), while no significant
differences in lung DVH are observed. Figure 5.1 (E) shows a line dose profile across the center
of the target for the three treatment plans. While there is reasonable dosimetric agreement at
the level of the patient midplane, there is lower dose through the tissue/air interface in the
MCrecalc profile (dotted line) compared to the PBopt (solid line) and MCopt (dashed line)
profiles.

Figure 5.1. PBS dose distributions for a lung cancer patient using three techniques: clinically approved analytical
pencil beam (PB) optimization and calculation (A), Monte Carlo (MC) re-calculation of the approved PBoptimized treatment plan (B) and MC optimized plan (C). Figures A, B and C show the dose distributions (colored
isodose lines) for each planning technique overlaid on the planning CT and clinical target volume (CTV, greenfilled contour). The bottom left figure (D) show DVH curves for the CTV (green) and lung (blue). Figure D shows
line dose profiles for each of the three techniques (solid line: PB-optimized, dotted line: MC-recalculation of PBoptimized plan, dashed line: MC-optimized plan).

Table 5.1 summarizes dose statistics for the total lung and CTV between the PBopt, MCrecalc
and MCopt treatment plans. In this 10-patient sample, CTV V95 ranged from 99% to 100%
with a median of 100% for PBopt plans. For MCrecalc plans, CTV V95 ranged from 77% to
94% with a median of 90%, a statistically significant drop in target coverage relative to PBopt
(p < 10-5). For the MCopt plans, CTV V95 ranged from 99% to 100% with a median of 100%,
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a significant recovery in target coverage (p < 10-5). Overall, MC treatment plans showed a
reduction of dose homogeneity within the target volume. The median CTV HI (D95/D5) was
0.98 for PBopt, 0.91 for MCrecalc and 0.95 for MCopt (p < 10-3). Analysis indicated that the
total lung V20 values were not statistically different among dose calculation and optimization
scenarios, with median V20 within 2% between PBopt (25%), MCrecalc (25%) and MCopt
(27%, p = 0.27). Median lung VRX was 7%, 1% and 8% for PBopt, MCrecalc and MCopt plans
respectively (p <10-3), indicating a reduction in lung volume receiving high dose when
recalculated with MC. Finally, the global patient max dose increased from a median value of
106% for PBopt to 109% and 112% for MCrecalc and MCopt, respectively (p < 10-3), using
fixed levels of MC statistical uncertainty.

Pencil Beam:
Optimized

Monte Carlo:
Recalculated

Monte Carlo:
Optimized

Median

Range

Median

Range

Median

Range

CTV V95

100%

99% - 100%

90%

77% - 94%

100%

99%-100%

< 10-5

CTV HI
(D95/D5)

0.98

0.95 - 1.00

0.91

0.87-0.94

0.95

0.94-0.98

< 10-3

Total
Lung V20

25%

15% - 35%

25%

16% - 34%

27%

20%-37%

0.27

Total
Lung VRX

7%

2% - 11%

1%

0% - 6%

8%

3%-11%

< 10-3

Global
Max Dose

106%

101% - 113%

109%

104% 122%

112%

105%-121%

< 10-3

Friedman P

Table 5.1. CTV V95, CTV homogeneity index (HI), total lung V20, total lung VRX and max point dose for ten
previously-treated lung patients using PB and MC dose calculation.

Perturbed dosimetric
parameters (3%/3mm)

Monte Carlo: recalculated

Monte Carlo: reoptimized

Wilcoxon
sign‐rank P
value

Median

Range

Median

Range

CTV D95

‐6%

[‐9%, ‐2%]

‐1%

[‐2%, 0%]

0.006

Global Max Dose

2%

[‐3%, 8%]

1%

[‐3%, 6%]

0.10

Table 5.2. CTV D95 and global max dose under perturbed scenarios of 3% beam over range and ±3mm isocenter shift in x, y and z.
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Given the inaccuracies of PB dosimetry, as summarized in Table 5.1, robustness evaluation was restricted to
plans utilizing only MC dose calculation.

Table 5.2 shows delta values representing the change in CTV D95 and global max dose for
MCrecalc and MCopt treatment plans under range and setup perturbations: (± 3% density /
under-range, x ± 3mm, y ± 3mm, z ± 3mm). Median change under perturbation in CTV D95
was -6% and -1% for MCrecalc and MCopt plans, which presented a statistically significant
improvement in plan robustness when optimizing with MC (p = 0.006). Change in global
maximum dose under perturbations was not statistically different between MCrecalc and
MCopt plans (p = 0.10), indicating that this parameter was most influenced by statistical noise
in both planning scenarios.

5.4 Discussion
In Saini et al. (47) it was demonstrated that analytic algorithms such as PB lack proton dose
calculation accuracy in highly heterogeneous media typically encountered during lung cancer
treatments. In another study by Saini et al. (11), PB and MC dose calculation algorithms were
benchmarked against measurements and it was found that MC provided superior dosimetric
accuracy, most notably in heterogeneous media. Similarly, Lin et al. (90) benchmarked the
Eclipse Acuros PTTM (Varian Inc., Palo Alto, CA) dose calculation algorithm. In this clinical
study, analysis of lung cancer patient treatment plans optimized with a commercial PB
algorithm and subsequently recalculated with Acuros PTTM demonstrated a median decrease in
CTV V95 by 10% (90). These results from Lin et al. also agree with recent findings by Taylor
et al, in which measurements from an anthropomorphic lung phantom concluded that use of
analytic dose algorithms under-dosed target centers by an average of 7.2% (49). The MC
planning results presented in this chapter are similar with those of Schuemann et al. (43, 44),
in which a mean decrease of 11% in tumor control probability of lung cancer from MC
dosimetry of analytic PB-optimized plans was observed. While these investigations
summarized the deficiencies in PB algorithms, the impact of MC-based optimization on
planned dosimetry of lung cancer patients was not addressed.
While a reduction in target dose was observed when recalculating with MC, CTV coverage
under MC-based plan optimization was statistically similar to that achieved in the original PBbased optimization. This illustrates that when changing from PB to MC dose calculation, target
coverage is lost but can be regained when MC optimization is employed. Similarly, a reduction
in dose homogeneity between PB-optimized (CTV HI = 0.98) and MC-recalculated plans (CTV
HI = 0.91) was observed. However, unlike target coverage, dose homogeneity is not fully
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regained when MC optimization is used (CTV HI = 0.95). These results demonstrate that a
similar target coverage in lung lesions can be expected when optimizing with PB and MC with
the caveat of reduced dose homogeneity under MC-based treatment planning/optimization.
Differences in normal lung tissue dosimetry were less pronounced for large volumes receiving
low/moderate dose but similar in magnitude for small volumes receiving high dose compared
to differences in target dosimetry. Total lung V20 remained within a ±2% deviation across the
three dose calculation techniques, and similar trends were observed for V10 and V5. Dose
differences in VRX showed a similar trend as CTV coverage across the different dose
calculation/optimization techniques. Changing from PB to MC-recalculated, VRX was reduced
from 7% to 1% but increased to 8% under MC- optimization. Regions of high dose in lung
proximal to targets and tissue interfaces were most affected by differences in the dose
calculation algorithm. This trend held true for other OARs, though their nominal dosimetry
was very specific to patient anatomic geometry and tumor size/location. For example, cases in
which the spinal cord was a dose limiting structure produced large variability in maximum dose
between PB and MC dose calculation algorithms.
Analysis of median global maximum dose showed an increase from 106% to 109% for PBoptimized and MC-recalculated plans respectively, and a further increase to 112% for MCoptimized plans. It’s worthwhile noting however that MC calculation statistical uncertainty can
impact maximum point doses. As a fixed statistical uncertainty of 0.5% was used in this study,
maximum dose may have been decreased further in some cases by further reducing the
statistical uncertainty setting. Decreasing the statistical uncertainty increases the number of
simulated ions which improves the precision of MC dose calculation at the expense of increased
calculation time.
Interestingly, robustness analysis revealed differences in perturbed dosimetry between the MCrecalculated and MC-reoptimized treatment plans. Plans that were robustly optimized with PB
and recalculated with MC had a median change in CTV D95 of -6% under 3%/3mm perturbed
dose scenarios. In contrast, plans robustly optimized with MC had a negligible median change
of -1% under 3%/3mm perturbed dose scenarios. These results are relevant for isocentric setup
perturbations that are orthogonal to an air/tissue/bone interface for any beams directed parallel
to the interface because under these conditions PB-optimized plans inaccurately estimate lateral
dosimetry from an infinite slab approximation for each pencil beam and consequently fail to
build in robust margins. Contrastingly, MC-optimized plans account for this dosimetric
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uncertainty by accurately estimating lateral spread along the interface from individual particle
interactions. Unlike target coverage, there was no significant difference in global maximum
dose between MC-recalculated and MC-optimized plans. This suggests that the effect of the
robust optimization algorithm was smaller compared to the effect of statistical MC uncertainty
on point doses.
The work presented in this chapter provided dosimetric evaluations of MC-based plans for lung
proton PBS treatments. Further analyses within this study was constrained by several
limitations. First, the cohort was limited to 10 patients and future work in this area could be
extended to a larger patient population, including subgroup analysis by disease stage, tumor
location, magnitude of tumor motion, and beam configuration. Furthermore, while all patients
in this study received definitive lung cancer proton beam therapy, there was substantial
variation in the size and location of target volumes across the patient cohort. The large variation
in target size and location resulted in a high degree of variability in dose to OARs across the
patients. For this reason, critical OARs exhibiting high variability and/or null dose (e.g. heart,
esophagus, spinal cord and brachial plexus) were excluded from this analysis. Finally, patient
dose calculation/optimization was performed on the 4DCT average and not on any of the
individual respiratory phases which could result in variations to the reported results. Future
work integrating MC robust optimization under perturbation of intra-fraction tumor motion, by
calculating 4D MC dose distributions (91) on 4DCT phases while accounting for PBS
respiratory-synchronized delivery timing, could prove valuable in improving lung proton
therapy safety and efficacy.

5.5 Conclusions
In conclusion, a retrospective analysis of lung cancer patients receiving PBS treatments
demonstrated

deficiencies

in

target

coverage

when

using

PB-based

dose

calculation/optimization. The presented analysis demonstrated that these deficiencies were
successfully resolved using a MC-based treatment plan design. Robust optimization with MC
planning had reduced sensitivity to range and setup perturbations compared to robust
optimization using PB-based dose calculation/optimization. Considering these findings, this
work advocates for clinicians to consider adoption of MC-based treatment planning of lung
cancer patients receiving PBS treatments.
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CHAPTER 6: A MACHINE LEARNING-BASED
FRAMEWORK FOR DELIVERY ERROR
PREDICTION IN PROTON PENCIL BEAM
SCANNING USING IRRADIATION LOG-FILES
The results presented in this chapter have been published in the European Journal of Medical
Physics:

Maes D, Bowen SR, Regmi R, Bloch C, Wong T, Rosenfeld A, et al. A machine learningbased framework for delivery error prediction in proton pencil beam scanning using irradiation
log-files. Physica Medica. 2020;78:179-86.
Author Contributions:
This project was led and organized by DM. Model training and testing as well as data analysis
was done by DM. Figures and text were composed by DM in consultation with SB, RR, CB,
TW, AR and JS.

6.1 Introduction
During PBS irradiation, scanning magnets, ionization chambers and various other components
precisely steer beam spots to irradiate the target volume while minimizing dose to healthy
tissue. Although these beam-line components are calibrated to ensure accurate beam
positioning and intensity, delivery errors in spot positions and intensity (i.e. MU) can
accumulate, resulting in changes to the delivered dose distributions within patients.
Various studies have demonstrated the successful use of PBS irradiation log-files for
reconstruction of delivered dose within patient anatomy (92, 93). In a study by Meier et al.
validation of an in-house software used for reconstruction of delivered dose distributions
utilizing PBS log-file data was investigated. In another study Zhu et al. used log-file data for
PBS patient-specific QA measurements (93). Scandurra et al. demonstrated the successful use
of log-file-recorded spot parameters to reconstruct dose distributions on clinical patient CT
scans and reported a mean gamma pass rate of 96.4% between nominal and reconstructed dose
across 37 patient treatments (94). Other studies have demonstrated the ability to utilize
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delivered spot parameters from log-files to quantify and assess the dosimetric effect of delivery
error of PBS beams on patient treatments (95, 96). Li et al. investigated differences between
planned and recorded spot parameters by analysing PBS irradiation log-file data across 14
patient treatments and found standard deviation values of 0.26 mm and 0.42 mm for x and y
spot positional delivery errors respectively (95). Finally, Belosi et al. (96) found that large dose
deviations are possible for highly modulated proton PBS plans thus systematic delivery errors
are important to consider for such cases during treatment planning.
Although log-file data allows for off-line review of PBS delivery error during patient
treatments, it is ideal to predict this error up-front during the planning phase. Predicting PBS
delivery error prior to treatment enables the planner to introduce mitigation strategies that can
minimize the effect of this uncertainty. These errors in proton PBS are analogous to multi-leaf
collimator (MLC) positioning errors in photon IMRT and VMAT delivery in which differences
between planned and delivered MLC positions and MU can result in changes to delivered dose
distributions within patient anatomy. As discussed in Chapter 2, multiple studies have
investigated the use of machine/deep learning algorithms to predict delivery uncertainties in
IMRT and VMAT delivery (65, 68, 97, 98). Carlson et al. demonstrated the use of ML models
to accurately predict MLC leaf position errors in VMAT treatment plans (65) and showed
improved gamma pass rates of measured vs. calculated profiles by incorporating the predictions
into the TPS-calculated profiles. Valdes et al. reported use of an analytical model to accurately
predict gamma pass rates (measured vs. TPS) of IMRT treatments based on various plan
complexity parameters including MU, MLC leaf positions and machine type (68). Tomori et
al. leveraged a CNN to accurately predict patient specific QA gamma pass rate values for
prostate treatments based on PTV/OAR volume and MU parameters (97).
While these studies have focused on prediction of delivery error for LINAC-based treatments,
the utilization of ML for predicting delivery error in proton PBS has not been investigated. The
aim of this chapter is to investigate the use of ML for prediction of delivery error of PBS beam
spots using an irradiation log-file dataset generated from a cohort of previously-treated prostate
patients. The multitude of recorded spot parameters extracted from the log-files allows for the
training of an ML model that can infer both linear and non-linear relationships between plan
parameters and log-file-derived delivery errors. In addition to demonstrating the feasibility of
using ML to predict delivery error in PBS, this chapter also presents a framework for delivery
error prediction that can be incorporated into a commercial TPS. As will be shown in this
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chapter, this framework can be used to evaluate dosimetric effects of PBS delivery error prior
to treatment, during the planning phase.

6.2 Methods
6.2.1 PBS treatment plans
A retrospective patient dataset of 20 PBS prostate plans were selected from the clinical TPS
database at SCCAPTC. The set of treatment plans consisted of 7 low risk (prostate only), 11
intermediate risk (prostate and seminal vesicles) and 2 high-risk prostate (prostate, seminal
vesicles and pelvic nodes) targets. All prostate patients were positioned FFS and treatment
planning was carried out using a lateral (left and right) beam arrangement. Low-risk prostate
target volumes were treated with one field per day and utilized a total of two beams to treat the
PTV to a dose level of 7920 cGy across 44 treatment fractions. Intermediate-risk prostate
patients were also treated with one field per day and used a total of four beams for treatment in
which beams 1 and 2 were used to treat the prostate and seminal vesicles to an initial dose of
5040 cGy in 28 treatment fractions while beams 3 and 4 treated the prostate to a total dose of
7920 cGy in 16 fractions. High-risk prostate target volumes were treated with 2 fields per day
and used a total of 4 beams per treatment with beams 1 and 2 treating the prostate, seminal
vesicles and pelvic nodes to total dose of 5040 cGy in 28 treatment fractions while beams 3
and 4 boosted the prostate to total dose of 7920 cGy in 16 treatment fractions.
For this work, all treatments were planned using the Raystation TPS utilizing PB dose
calculation. All plans were calculated on patient CT datasets using an isotropic dose calculation
grid size of 3 mm. Treatment fields were optimized using an initial spot placement target
margin of 0.8 cm around the PTV as well as variable energy layer and inter spot-spacing
parameters relative to the Bragg peak width and spot size, respectively (energy spacing = 0.8
cm, spot spacing = 0.8 cm). Optimization objectives were adjusted such that each beam was
optimized to deliver a uniform dose distribution across the PTV. In total, the planning data set
consisted of 66 beams and 123,079 PBS beam spots ranging in energy from 132.6 MeV to
219.2 MeV.

6.2.2 Assessment of PBS delivery error
For each patient treatment beam, planned spot positions and MU were extracted from DICOMRT files exported from the TPS and treatment fields were delivered on a fixed PBS beamline.
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Following treatment, irradiation log-files were extracted from the proton delivery system.
Recorded spot positions and MU were extracted from the log-files using REGGUI, a
MATLAB-based software package that supports analysis of PBS irradiation log-files for PBS
beams delivered with the IBA system (99). Validation of the REGGUI log-file analysis
functionality has been carried out using a 2d-scintillator detector by Toscano et al. (100). Each
set of planned spot parameters (i.e. spot position, MU and energy) extracted from the DICOMRT files was matched to the corresponding set of delivered spot parameters extracted from the
log files. Spot parameters were compiled into a centralized dataframe where each row
contained planned and delivered spot parameters (i.e. x/y position and MU) for each given spot.
This collection of planned and delivered spot parameters formed the primary dataset which was
used to quantify spot positional and MU delivery errors.
Next, the effect of PBS delivery errors on a dose distribution within patient anatomy was
investigated. This was carried out by first extracting delivered spot positions and MU from two
fractions of a previously-treated prostate treatment. This test patient had a low-risk prostate
target and was previously treated using the corresponding treatment schema as described in
section 6.2.1. Delivered spot parameters from this patient were extracted from irradiation logfiles and inserted into a DICOM-RT file which was imported into the TPS and the
corresponding dose distribution was calculated on the patient CT using PB dose calculation.
Target/OAR DVH curves and corresponding dose distributions were evaluated on the original
and delivered plan.

6.2.3 Machine learning model training and validation
In this work three ML model types were selected for use: 1) linear regression, 2) random forest
and 3) neural network. Training/tuning/testing of these ML models was carried out in the
following manner: First, the primary dataset consisting of planned/delivered spot parameters
was randomly split into two separate data sub-sets used for (1) training and (2) testing where
80% of the data was used for the training set and 20% was reserved for the testing set. During
this random split, planned/delivered spot parameters were randomly extracted from the primary
dataset such that the training and test datasets contained a stratified mixture of spot parameters
across all patients used in this study. In the training dataset, features and targets were defined
and each ML model was trained to predict spot parameter targets (i.e. delivered spot positions
and MU) based on spot parameter features (i.e. planned spot positions and MU) as illustrated
in Figure 6.1 (a).
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Figure 6.1. Diagram showing the feature and target variables used for training of ML models (a) and workflow
of model tuning/training/testing (b).

Model hyper-parameter tuning was carried using 5-fold cross validation with MAE as the
model evaluation metric. Upon each iteration of hyper-parameter tuning, various combinations
of model settings were varied and then used for cross validation. This process was repeated for
multiple iterations for the random forest and neural network model until the MAE was
minimized. The trained model using the optimal combination of hyper-parameter settings
yielding the lowest MAE values was then used as the basis for model selection between the
different machine learning algorithms. Table 6.1 shows the different combinations of hyperparameter settings used during cross validation of the random forest and neural network
models.

Table 6.1. Hyper-parameter settings used during tuning of the random forest and neural network models.

Note that the linear regression model used in this study only fits linear regression coefficients
and did not contain any hyper-parameters to tune. Therefore, in the case of the linear regression
model, testing was carried out immediately after training. Following completion of hyper-
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parameter tuning, model selection was carried out again using MAE as the evaluation metric.
Next, the selected trained model was used to make predictions on the testing data set and the
resulting MAE was reported. To verify the model was not over-fitting the training data, MAE
was reported for both predictions made on the training and testing datasets.

6.2.4 Machine learning models
ML models used in this chapter were implemented in the python programming language using
the Scikit-Learn machine learning library version 0.22.2 (101). The following three sections
briefly describe the ML models used in this study as well as final hyper-parameters selected
following model tuning.

6.2.5 Linear regression model
The linear regression model is a supervised ML model that utilizes ordinary least squares
regression as described in Ari et. al. and Saunders et. al. (102, 103). The function in Scikitlearn known as LinearRegression was used to fit a linear model to minimize the residual sum
of squares between targets within the spot parameters dataset and the spot parameters predicted
by linear approximation.

6.2.6 Random forest model
The random forest model implemented in this chapter is a random forest regression model and
is primarily based on algorithms described in Breiman and Geurts et al. (66, 104). In the
implementation of this model, data is first divided into numerous sub-samples. For each
subsample, the features are used to build a decision tree and this process is repeated until a
decision tree is constructed for each sub-sample resulting in collection of trees referred to as a
forest. To make predictions, testing data elements are iteratively ran through decision trees
within the forest. Prediction values are calculated by averaging the output of all decision trees.
In this work, 100 sub-samples were generated resulting in 100 decision trees that were built
using 4 features at each split. These four features were spot position (x any y), MU and energy.
Other hyper-parameter settings included use of bootstrapping meaning that each decision tree
was built from a sub-sample comprised of randomly selected elements from the training data
set.
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6.2.7 Neural network model
The neural network model implemented in this chapter is described in Murtagh et al. (105).
This model utilizes an algorithm known as a multilayer perceptron (MLP) which is a class of
neural networks. The MLP used in this work consisted of three layers where each layer is
composed of a set of binary classifiers known as perceptrons. The first layer, known as the
input layer, consists of a set of neurons that represent the input features. In this study, four
neurons were used in this layer, one for each feature: planned spot positions (x any ), MU and
energy extracted from the DICOM-RT files. The second layer, known as the hidden layer,
consisted of a set of neurons that transform values from the input layer using a non-linear
activation function. Here the hidden layer consisted of 100 neurons using the rectified linear
activation function for non-linear weighting of neuron inputs. The final layer known as the
output layer receives values from the hidden layer and transforms them into output values.
Through the method of backprojection (106), neuron weights throughout each layer are
iteratively optimized using Adam, an adapted stochastic gradient-based optimization technique
which is described in Kingma et al. (107). The max number of iterations for optimization of
neuron weights was set to 200 using a regulariztion term of 0.0001 to prevent overfitting of the
training dataset. Just as the random forest and linear regression models, the final output of the
neural network model were predicted delivery values of spot position and MU.

6.2.8 Prediction of delivered dose distribution on patient anatomy
A previously-treated prostate plan and corresponding log-file delivery record was selected to
quantify the prediction accuracy of the ML model with the best prediction accuracy. This
prostate plan was not included in the training data set to ensure unbiased verification of our
trained model. The treatment plan was used as an input to the trained ML model to obtain
predicted spot parameters. Finally, these predicted spot parameters were used to create a TPScompatible DICOM-RT file that was imported into the Raystation TPS to generate a predicted
dose distribution. Furthermore, log-file parameters of the delivery of two fractions of the plan
were used to extract delivered spot parameters. Like predicted spot parameters, the delivered
spot parameters were inserted into a DICOM-RT file so that log-file-delivered dose distribution
could be calculated on the patient’s CT within the TPS. The result was a three-way dose
comparison between (1) original treatment plan, (2) predicted delivery, and (3) log-filerecorded delivery.
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6.3 Results
6.3.1 Assessment of PBS spot delivery error
The spot positional delivery error was analyzed using histogram plots where each bin is the
difference between the planned spot positions and delivered spot positions extracted from the
log-files. Applying a Gaussian fit to this data yielded standard deviation values of 0.39 mm and
0.44 mm and mean values of -0.1 mm and 0 mm for the x and y positional delivery errors
respectively as shown in Figure 6.2.

Figure 6.2. Gaussian fit of histogram plots with respective standard deviation (σ) and mean (µ) values for x and
y positional delivery error between delivered and planned spot parameters.

A similar histogram of the MU delivery error was generated where each bin is now the
percentage error between planned and delivered MU for each spot in the training dataset.
Results show a non-normal distribution that is biased towards the positive x-direction as can
be seen in Figure 6.3.
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Figure 6.3. Histogram plot of the percent error of MU delivery between planned and delivered beam spots.

To demonstrate the effects of delivery errors on dose distributions within patient anatomy,
delivered spot parameters from a log-file were used for dose calculation on a low-risk prostate
patient CT. Calculated dose distributions of the original treatment plan (Plan) and delivered
plan calculated with spot parameters extracted from the corresponding log-file (Plan-Logs) are
shown in Figure 6.4.

Figure 6.4. Dose distributions in color wash of Plan (a) and Plan-Logs (b) with the prostate PTV (red contour).
Here Plan refers to the nominal plan and Plan-Logs refers to the dose reconstruction using log-file data.

As can be seen in Figure 6.4, dose differences between Plan and Plan-Logs are most significant
at higher iso-dose levels, inside and near the PTV. Figure 6.5 shows a dose difference between
the Plan and Plan-Logs which allows for better visualization of the differences between these
two plans.

Figure 6.5. Dose difference color wash between Plan and Plan-Logs.
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6.3.2 Model selection
Figure 6.6 shows a bar plot of MAE for the prediction of spot positions (x and y coordinates)
and MU using the trained linear regression, random forest and neural network ML models.

Figure 6.6. Bar plot showing MAE for the prediction of x-spot position, y-spot position and spot MU across three ML
models: random forest, neural network and linear regression.

As mentioned in Section 6.2.3, MAE values were calculated during cross validation of the
training dataset. Cross validation of the trained random forest model resulted in MAE values
of 0.15 mm, 0.13 mm and 0.01 MU for prediction of x-spot positions, y-spot positions and spot
MUs respectively. Cross validation of the neural network model resulted in MAE values of
0.33 mm, 0.70 mm and 0.02 MU for prediction of x-spot positions, y-spot positions and spot
MUs respectively. Finally, cross validation of the linear regression model resulted in MAE
values of 0.33 mm, 0.68 mm and 0.01 MU for prediction of x-spot positions, y-spot positions
and spot MUs respectively. As shown in Figure 6.6, the random forest model had the lowest
MAE for prediction of spot x and y positions. Compared to the linear regression model the
random forest model had slightly larger MAE for prediction of MU however. Despite this fact,
this study choose to implement the random forest model as another study (100) has reported
that delivery errors in spot position have a much more significant impact on treatment plan
quality than MU delivery errors.

6.3.3 Random forest model evaluation
Further quantification of the prediction accuracy of the trained random forest model is
presented in Figure 6.7 which shows histogram plots of the x and y positional prediction error
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where each bin is the difference between log-file-recorded position and predicted position
using the trained random forest model on the testing dataset.

Figure 6.7. Histogram plot of the difference between random-forest-predicted and log-file-recorded x and y spot
positions with associated Gaussian curves using the test dataset.

As shown in Figure 6.7, the Gaussian curve fit to the positional error bins had standard
deviation values of 0.22 mm and 0.11 mm and mean values of 0 mm for the x and y positional
prediction errors respectively.
To ensure model over-fitting was not occurring, MAE prediction values were analyzed for
model predictions of spot parameters using the training and testing datasets. Figure 6.8
compares the MAE of the random forest model predictions of spot parameters using training
and testing data.

Figure 6.8. MAE values for random forest model-predicted spot parameters using the training and testing data sets as model
inputs.

92

As seen in Figure 6.8, compared to the training dataset a slight decrease in MAE when
performing predictions on the testing dataset was observed. The percent difference in MAE for
spot parameter prediction was -10.2%, -12.3% and -3.2% for x-spot position, y-spot position
and MU respectively. Because MAE of the random forest model predictions was slightly lower
for the testing dataset than the training dataset, it was concluded that the random forest model
was not over-fitting the data and was effective in making predictions on unseen data.
Next, a three-way comparison of dose distributions and DVH data was evaluated for Plan, PlanLogs and the plan predicted by the random forest model (Plan-RF). Figure 6.9 shows the three
plans for the same example patient that was presented in Figure 6.4.

Figure 6.9. Three-way comparison of dose distributions for Plan (a) Plan-Logs (b) and Plan-RF (c) with the PTV
target volume contoured in red.

As can be seen in Figure 6.9, visual differences in the dose distribution between Plan and PlanLogs are more substantial than differences between Plan-Logs and Plan-RF indicating that the
random forest model can effectively predict delivered dose distributions. Figure 6.10 shows
DVH curves for the three dose distributions shown in Figure 6.9 for the PTV and several OARs.
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Figure 6.10. DVH curves for the PTV and several relevant OARs corresponding to Plan, Plan-Logs and PlanRF.

As can be seen in Figure Figure 6.10, DVH curves for Plan, Plan-Logs and Plan-RF are very
similar for OARs (i.e. the bladder, rectum and right femoral head) which are primarily located
in low-dose regions within the patient anatomy. In contrast, more prominent differences can be
observed in the DVH curve for the PTV. As shown in Figure 6.10, reduction in prescription
iso-dose coverage is observed when comparing the Plan to Plan-Logs. Comparison of DVH
curves demonstrates that this loss in prescription iso-dose coverage is accurately predicted by
the trained random forest model.

6.4 Discussion
In this study delivery error of a fixed IBA PBS beam-line was characterized by comparing
planned spot parameters extracted from DICOM-RT files to the delivered parameters extracted
from the corresponding irradiation log-files. As presented in Figure 6.2 the resulting x and y
positional delivery errors were calculated to be 0.39 mm and 0.44 mm respectively. Similar
analysis of spot positional delivery error was studied by Toscano et al. and Li et al. (95, 100).
In the paper by Toscano et al. PBS delivery error of an IBA beam-line was investigated using
standardized spot patterns and corresponding log-files which were extracted following beam
delivery. The reported standard deviation values for spot positional accuracy in this work were
0.57 mm and 0.58 mm for the x and y positions respectively (100). In the other study by Li et
the delivery error of the Hitachi PROBEAT proton PBS delivery system (Hitachi, Ltd., Tokyo,
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Japan) was studied using log-file data across 14 patient treatments. The reported standard
deviation values for positional PBS beam spot delivery errors in this work were 0.26 mm and
0.42 mm for x and y respectively (95).
Compared to the work presented in this chapter, the positional delivery errors reported by
Toscano et al. are slightly larger than the values reported in this work which can be attributed
to multiple variables. First, Toscano et al. analyzed standardized spot patterns which spanned
across a larger field size and range of energies whereas the field sizes presented in this chapter
were smaller and limited to energy ranges used for the treatment of prostate targets. Future
work can expand to multiple disease sites which would utilize larger field sizes and more
variable energy ranges. Other discrepancies between this study and that reported by Toscano
et al. and Li et al. could be attributed to differences in machine type and technique. In this work,
log-files were analyzed from a fixed PBS beam-line whereas Toscano et al. used log-file data
from a rotational gantry across various beam angles and Li et al. utilized completely different
proton therapy vendor/beam delivery system.
Various studies have demonstrated the use of ML models for the prediction of MLC leaf
positioning and MU errors and the resulting effect on dose distributions within patient anatomy
for IMRT and VMAT treatments (65, 68, 97, 98) as discussed in Chapter 2. Like IMRT and
VMAT, the work presented in this chapter demonstrates that delivery errors in PBS proton
therapy can impact dose distributions within patient anatomy. PBS log-files comprise a wealth
of beam delivery data allowing for accurate characterization of PBS delivery errors. The large
amounts of beam data in log-files is suitable for effective training/testing/tuning of ML models
for the prediction of PBS delivery errors. This work has demonstrated the novel use of ML
algorithms to predict delivered PBS spot parameters using irradiation log-file data as a training
dataset. Dose distributions generated by the presented random forest model were evaluated on
patient anatomy. Isodose distributions and DVH data between the approved plan and log-file
delivery show a reduction in prescription isodose coverage for a test prostate PTV while good
agreement was observed between the log-file delivery and predicted dose distributions using
the trained random forest model.
When interpreting differences in dose distributions between the approved plan and
reconstructed log-file plan it is also important to consider any uncertainties associated with the
recording of spot parameters to the log-files. In the study by Toscano et al. it was reported that
some discrepancies between a nominal treatment plan and log-file-reconstructed-plan can be
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attributed to uncertainties inherent to the log-file data (100). These log-file uncertainties arise
from a limitation of the beam-line ionization chambers for the measurement of delivered PBS
beam spot positions. The beam-line ion chambers rely on vertical and horizontal wire strips of
limited spatial resolution and determination of spot positions across these strips requires
interpolation of a three-point-based Gaussian fit which can result in uncertainties of the same
order of magnitude as the delivery errors calculated from the log-file data (100). To account
for this uncertainty, Toscano et al. benchmarked log-file-derived spot parameters against
measurements. This data was used to characterize the random and systematic components of
log-file uncertainties and a lookup table to correct for these errors was generated. Future work
will include a similar benchmarking of the log-file data presented in this work against
measurements to characterize associated uncertainties in predicting delivered dose distributions
using the trained random forest model.
This work presented in this chapter had the following limitations. First, the predicted dose
distribution was evaluated on only a single prostate patient using only 2 fractions of log-file
delivery data. Additional future work can expand to evaluate ML model accuracy on a broader
set of patients and disease sites utilizing a comprehensive set of log-files across all delivered
treatment fractions. Analysis of PBS log-file data across all fraction deliveries will allow for
enhanced quantification of the effect of delivery errors on dose distributions within patient
anatomy. Finally, utilization of a trained ML model enables the possibility to mitigate the dose
degradation caused by PBS delivery error. One mitigation strategy could be to intentionally
introduce small perturbations in the planned PBS spot parameters based on predicted
parameters to proactively correct for this delivery error. Such an application of a trained ML
model would also serve as basis for future studies of this topic.

6.5 Conclusion
This study demonstrated the use of an ML model to accurately predict delivered PBS spot
positions and MU using information from irradiation log-files as part of a training dataset. Logfile data along with treatment planning data from DICOM-RT files across 20 PBS patient plans
was used to train three different types of ML models to predict delivered PBS spot parameters
based on planned parameters. Validation results show that the random forest model had the
lowest MAE compared to the neural network and linear regression models for prediction of the
delivered PBS spot parameters. Finally, a scripting framework was developed to 1) reconstruct
delivered dose in commercial TPS using delivered spot parameters extracted from PBS
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irradiation log-files and 2) calculate a dose distribution using the predicted spot parameters as
generated from the ML model. Analysis of dose distributions and DVH data for a prostate
patient indicate that the trained random forest model was effective in accurately predicting the
delivered dose distributions within patient anatomy for a prostate patient using limited number
of treatment fractions.
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CHAPTER 7: CONCLUSIONS
7.1 Summary
This thesis has explored various methods in which to improve PBS delivery for the treatment
of cancer. The research carried out in this thesis has been conducted at the Seattle Cancer Care
Alliance Proton Therapy Center along with the support of the University of Wollongong,
Centre for Medical Radiation Physics. Furthermore, the work conducted in this thesis has
served as the basis of clinical implementation of various PBS treatment techniques aimed at
improving PBS beam delivery at SCCAPTC. It is the intention of this thesis that the presented
work can be used as the basis for clinical implementation of similar technology and techniques
in other proton therapy clinics. The following sections re-visit the specific aims that were
presented in chapter section 1.2 and summarize key findings and conclusions of Chapters 3 6.
Aim 1: Investigation and implementation of aperture collimators for PBS
Chapter 3 investigated the use of aperture collimators for PBS treatments to sharpen lateral
penumbra. This work was motivated by the fact that penumbra sharpening of PBS beams can
result in a reduction of dose to critical OARs adjacent to the PTV for certain disease sites. The
work presented in this chapter was published in journal of Biomedical Physics & Engineering
Express and was the first to comprehensively characterize penumbra reduction (i.e. difference
in lateral penumbra with and without collimation) of collimated PBS beams as function of
relevant treatment planning parameters including airgap, range shifter thickness and beam
energy. Characterization of PBS lateral penumbra reduction included derivation of analytical
equations to fit the TPS-calculated penumbra reduction as a function of air gap and depth for
various range shifter thicknesses. Data analysis revealed that use of collimators for PBS beams
has the largest effect at shallow depths when using small airgaps. Penumbra reduction was 2.7
mm, 3.7 mm and 4.2 mm for RS0, RS45 and RS75 respectively. At deeper depths, penumbra
reduction was reduced to 1 mm at a depth of approximately 23 cm for RS0 and 20 cm for RS40
and RS75. Next, a clinical test brain patient was used to compare lateral penumbra with and
without use of PBS aperture collimation. Dosimetric analysis of the treatment plan for this test
patient showed enhanced lateral penumbra sharpening which was in good agreement with the
previously-presented analytical equation as well as enhanced OAR sparing for critical OARs
adjacent to the target. Finally, all TPS-calculated penumbra values were validated against film
measurements and were within ± 1mm indicating that the dose calculation of collimated PBS
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beams was accurate and acceptable for clinical use using the Raystation MC dose calculation
algorithm.
Aim 2: Clinical validation of PBS treatments in the seated position
In Chapter 4, a commercial TPS implementation of a treatment chair for a fixed proton
beamline was validated. This work was published in Physica Medica and was the first to
present a comprehensive validation of the treatment chair implementation within the Raystation
TPS known as the 6D couch. Validation of the chair pitch and roll capabilities within
Raystation was performed through creation of phantom plans that compared (1) TPS-generated
DRRs with planar x-rays in the treatment room and (2) TPS-calculated dose profiles against
ion chamber array measurements. The DRRs were found to have an acceptable agreement with
planar x-rays based on visual inspection and for the dose map comparison between measured
and calculated, gamma index analysis for all measured beams was >95% at a 3% dosedifference and 3 mm distance-to-agreement tolerances. Finally, for end-to-end testing, an
anthropomorphic phantom was successfully setup at isocenter in the seated position and a
treatment was delivered. These measurements concluded that the Raystation treatment chair
features were consistent with IEC 61712 standards are suitable for clinical treatments.
Validation of this treatment chair within the TPS will allow for its use in a fixed proton PBS
beamline at SCCAPTC.
Aim 3: Comparisons of PB and MC dose calculation in lung
Comparisons between MC and PB dose calculation for lung treatments was investigated in
Chapter 5. To highlight the dosimetric impact on treatment planning between these two dose
calculation algorithms, a comparative dosimetric analysis between MC and PB was performed
on ten lung patient plans using the Raystation TPS. Across this patient dataset, sample dose
differences between PB-optimized, MC-recalculated, and MC-optimized plans were recorded
for the CTV and several OARs for the nominal as well as perturbed dose scenarios to assess
the impact on robustness. Across the ten-patient sample, it was found that CTV V95 decreased
significantly from 99–100% for PB-optimized to 77–94% for MC-recalculated and recovered
to 99–100% for MC-optimized. This means that the use of PB dose calculation for lung
treatments can result in significant under-dosing of the target volume. As mentioned previously
in Chapters 2 and 5, Raystation’s MC dose calculation has been shown to have a high level of
accuracy within patient anatomy across a multitude of disease sites. Resultingly then, this work
strongly supports the use of MC dose calculation for PBS treatment planning for the treatment
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of lung lesions as well as other disease sites within highly heterogenous media to ensure
accurate dosimetry.
Aim 4: Application of machine learning for prediction of PBS delivery error
A machine learning framework for PBS delivery error prediction using irradiation log-file data
was explored in Chapter 6. In this work, PBS log-file data was extracted from a set of 20
prostate patient treatment deliveries. Delivered spot parameters (i.e. x-y position and MU) as
recorded in the log-files was compared against planned parameters to analyze the magnitude
of the delivery error of PBS beams. This analysis revealed that positional errors were Gaussian
in shape with standard deviations of 0.39 mm and 0.44 mm for the x and y positional delivery
errors respectively. The log-file and treatment planning data across the 20-patient sample was
used to train/test 3 ML models to predict the delivery error of PBS beams. Model testing
showed that the random forest regression model had the best performance for delivery error
prediction and was able to predict positional uncertainty to within a standard deviation 0.22
mm and 0.11 mm for x and y positions respectively. The random forest model was then used
as the basis of a scripting framework that allowed for generation of log-file-delivered as well
as ML-predicted dose distributions within the Raystation TPS for patient treatment plans.
Analysis of DVH data as well as dose distributions showed good agreement between the MLpredicted dose and log-file-delivered dose distribution. While the topic of delivery error
prediction using ML has been investigated for IMRT and VMAT delivery (see Section 2.4) the
published work presented in this chapter was the first to apply ML for the prediction of PBS
delivery error. The delivery error prediction framework presented here opens to door to the
possibility of pre-treatment review of dosimetric effects of PBS delivery error within a TPS
using predictive analytics.

7.2 Future Work
The work presented in this thesis builds a foundation for numerous future studies that address
novel improvements in PBS proton therapy. On the topic of using aperture collimators for PBS
delivery, the methodology presented in this thesis can be applied to the characterization of
lateral penumbra across different proton therapy vendors/systems. Future work on this topic
also includes further validation of the analytical equation for penumbra reduction as presented
in Chapter 3 which was tested against results from a single patient plan. Validation of the
analytical penumbra equation across multiple patients/disease sites would ensure the suitability
of this model as an accurate means to predict the penumbra reduction achieved when using
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PBS apertures. This knowledge can assist clinicians in making the decision of whether to use
apertures during the treatment planning phase.
The work carried out in Chapter 4 validates the clinical implementation of chair-based proton
therapy within the Raystation TPS allowing more flexibility in treatment planning on a fixed
beamline. Future work on this topic, currently underway, is to use Raystation’s chair model to
explore the feasibility of treating ocular melanoma patients on a fixed PBS beamline at
SCCAPTC. The increased flexibility of chair-based treatment planning will also enable
treatments of disease sites not normally treated on a fixed PBS beamline which can be the basis
of future studies.
The work carried out in Chapter 4 can be extended to further explore the impact of PB vs MC
dosimetry on complex disease sites beyond lung. Other future work on this topic relates to
improving on the dose calculation time when using a commercial MC dose engine. Recent
implementations of commercial MC dose engines are highly optimized and computation time
is much less compared to traditional MC codes used for proton beam transport (e.g. GEANT4
(108) ). Despite this reduced computation time, dose calculation/optimization for large fields
in highly heterogenous media can be significantly longer for MC compared to PB-based
treatment planning. Recently Raysearch Laboratories has released Raystation version 10A
which supports GPU-based dose calculation for the MC dose engine. Various studies have
shown significantly decreased MC calculation when using a GPU (109, 110). Future studies
will include validation of Raystation’s GPU-based MC dose engine as well as benchmarking
of calculation times.
Finally, on the topic of machine learning there are numerous future applications for improving
PBS treatments. One such study that is highly relevant to this thesis is to expand the prediction
of PBS delivery error to a proton beam delivery system that utilizes active aperture collimation.
One such implementation of this is Mevion’s Adaptive Aperture™ which uses a tertiary proton
PBS collimation system as described by Grewal et al. (22). In this system, delivery error can
be present in both PBS beam spot positions as well as aperture movements and analysis of this
system’s log-files could enable characterization of these delivery errors and correspondingly a
predicted ML-based framework like the one presented in Chapter 6 could be created for such
a system.

101

REFERENCES
1.

Wilson RR. Radiological Use of Fast Protons. Radiology. 1946;47(5):487-91.

2.

Slater JM, Archambeau JO, Miller DW, Notarus MI, Preston W, Slater JD. The proton
treatment center at Loma Linda University Medical Center: rationale for and description
of its development. International journal of radiation oncology, biology, physics.
1992;22(2):383-9.

3.

Lomax A. Intensity modulation methods for proton radiotherapy. Physics in Medicine &
Biology. 1999;44(1):185.

4.

Pérez-Andújar A, Newhauser WD, DeLuca PM. Neutron production from beammodifying devices in a modern double scattering proton therapy beam delivery system.
Physics in Medicine and Biology. 2009;54(4):993-1008.

5.

Titt U, Zheng Y, Vassiliev ON, Newhauser WD. Monte Carlo investigation of collimator
scatter of proton-therapy beams produced using the passive scattering method. Phys Med
Biol. 2008;53(2):487-504.

6.

Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers.
International Journal of Radiation Oncology*Biology*Physics. 2006;65(1):1-7.

7.

Cozzi L, Fogliata A, Lomax A, Bolsi A. A treatment planning comparison of 3D
conformal therapy, intensity modulated photon therapy and proton therapy for treatment
of advanced head and neck tumours. Radiotherapy and Oncology. 2001;61(3):287-97.

8.

Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, et al. Intensity-Modulated
Proton Therapy Reduces the Dose to Normal Tissue Compared With Intensity-Modulated
Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized
Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual
Clinical Study. International Journal of Radiation Oncology*Biology*Physics.
2010;77(2):357-66.

9.

Engelsman M, Schwarz M, Dong L. Physics Controversies in Proton Therapy. Seminars
in Radiation Oncology. 2013;23(2):88-96.
102

10. Paganetti H. Proton therapy physics. 2019.
11. Saini J, Maes D, Egan A, Bowen SR, St James S, Janson M, et al. Dosimetric evaluation
of a commercial proton spot scanning Monte-Carlo dose algorithm: comparisons against
measurements and simulations. Phys Med Biol. 2017;62(19):7659-81.
12. Liu H, Chang JY. Proton therapy in clinical practice. Chin J Cancer. 2011;30(5):315-26.
13. Saini J, Cao N, Bowen SR, Herrera M, Nicewonger D, Wong T, et al. Clinical
Commissioning of a Pencil Beam Scanning Treatment Planning System for Proton
Therapy. International Journal of Particle Therapy. 2016;3(1):51-60.
14. Baumer C, Geismar D, Koska B, Kramer PH, Lambert J, Lemke M, et al. Comprehensive
clinical commissioning and validation of the RayStation treatment planning system for
proton therapy with active scanning and passive treatment techniques. Phys Med.
2017;43:15-24.
15. Charlwood FC, Aitkenhead AH, Mackay RI. A Monte Carlo study on the collimation of
pencil beam scanning proton therapy beams. Med Phys. 2016;43(3):1462-72.
16. Bues M, Newhauser WD, Titt U, Smith AR. Therapeutic step and shoot proton beam spotscanning with a multi-leaf collimator: a Monte Carlo study. Radiat Prot Dosimetry.
2005;115(1-4):164-9.
17. Safai S, Bortfeld T, Engelsman M. Comparison between the lateral penumbra of a
collimated double-scattered beam and uncollimated scanning beam in proton
radiotherapy. Phys Med Biol. 2008;53(6):1729-50.
18. Dowdell SJ, Clasie B, Depauw N, Metcalfe P, Rosenfeld AB, Kooy HM, et al. Monte
Carlo study of the potential reduction in out-of-field dose using a patient-specific aperture
in pencil beam scanning proton therapy. Phys Med Biol. 2012;57(10):2829-42.
19. Perl J, Shin J, Schumann J, Faddegon B, Paganetti H. TOPAS: an innovative proton Monte
Carlo platform for research and clinical applications. Med Phys. 2012;39(11):6818-37.
20. Winterhalter C, Lomax AJ, Oxley D, Weber DC, Safai S. A comprehensive study of lateral
fall-off (penumbra) optimisation for pencil beam scanning (PBS) proton therapy. Phys
Med Biol. 2017.
103

21. Baumer C, Janson M, Timmermann B, Wulff J. Collimated proton pencil-beam scanning
for superficial targets: impact of the order of range shifter and aperture. Phys Med Biol.
2018;63(8):085020.
22. Grewal HS, Ahmad S, Jin H. Characterization of penumbra sharpening and scattering by
adaptive aperture for a compact pencil beam scanning proton therapy system. Medical
Physics.n/a(n/a).
23. Rahim S, Korte J, Hardcastle N, Hegarty S, Kron T, Everitt S. Upright Radiation
Therapy—A Historical Reflection and Opportunities for Future Applications. Frontiers in
Oncology. 2020;10(213).
24. Morrison R, Newbery GR, Deeley TJ. Preliminary Report on the Clinical Use of the
Medical Research Council 8 MeV Linear Accelerator. The British Journal of Radiology.
1956;29(340):177-86.
25. Boag JW, Hodt HJ. Adjustable chair for radiotherapy of head and neck cancer. The British
Journal of Radiology. 1971;44(520):316-7.
26. Miller RW, Raubitschek AA, Harrington FS, Van de Geijn Ovadia J, Ovadia J, Glatstein
E. An isocentric chair for the simulation and treatment of radiation therapy patients.
International journal of radiation oncology, biology, physics. 1991;21(2):469-73.
27. Whelan B, Welgampola M, McGarvie L, Makhija K, Feain I, Holloway L, et al. EP-1930:
Cancer patient experience of slow, single arc rotation to simplify radiation therapy
delivery. Radiotherapy and Oncology. 2016;119:S916.
28. Wiernik G. A new radiotherapy treatment chair. The British journal of radiology.
1961;34(406):676-8.
29. Watson G, Shuttleworth E, Deeley T. A radiotherapy treatment chair. The British journal
of radiology. 1971;44(520):317-8.
30. Kamada T, Tsujii H, Mizoe J-E, Matsuoka Y, Tsuji H, Osaka Y, et al. A horizontal CT
system dedicated to heavy-ion beam treatment. Radiotherapy and oncology.
1999;50(2):235-7.

104

31. Duisters C, Beurskens H, Nijsten S, Starmans M, Wanders S, Verschueren T, et al.
Palliative chest irradiation in sitting position in patients with bulky advanced lung cancer.
Radiotherapy and oncology. 2006;79(3):285-7.
32. McCarroll RE, Beadle BM, Fullen D, Balter PA, Followill DS, Stingo FC, et al.
Reproducibility of patient setup in the seated treatment position: A novel treatment chair
design. Journal of Applied Clinical Medical Physics. 2017;18(1):223-9.
33. Sheng Y, Sun J, Wang W, Stuart B, Kong L, Gao J, et al. Performance of a 6D Treatment
Chair for Patient Positioning in an Upright Posture for Fixed Ion Beam Lines. Frontiers in
Oncology. 2020;10(122).
34. Sheng Y, Sun J, Wang W, Stuart B, Kong L, Gao J, et al. Performance of a 6D Treatment
Chair for Patient Positioning in an Upright Posture for Fixed Ion Beam Lines. Frontiers in
oncology. 2020;10:122.
35. Buchner T, Yan S, Li S, Flanz J, Hueso-González F, Kielty E, et al., editors. A soft robotic
device for patient immobilization in sitting and reclined positions for a compact proton
therapy system. 2020 8th IEEE RAS/EMBS International Conference for Biomedical
Robotics and Biomechatronics (BioRob); 2020: IEEE.
36. Tourovsky A, Lomax AJ, Schneider U, Pedroni E. Monte Carlo dose calculations for spot
scanned proton therapy. Phys Med Biol. 2005;50(5):971-81.
37. Hotta K, Kohno R, Takada Y, Hara Y, Tansho R, Himukai T, et al. Improved dosecalculation accuracy in proton treatment planning using a simplified Monte Carlo method
verified with three-dimensional measurements in an anthropomorphic phantom. Phys Med
Biol. 2010;55(12):3545-56.
38. Paganetti H. Range uncertainties in proton therapy and the role of Monte Carlo
simulations. Phys Med Biol. 2012;57(11):R99-117.
39. Yamashita T, Akagi T, Aso T, Kimura A, Sasaki T. Effect of inhomogeneity in a patient's
body on the accuracy of the pencil beam algorithm in comparison to Monte Carlo. Phys
Med Biol. 2012;57(22):7673-88.

105

40. Bueno M, Paganetti H, Duch MA, Schuemann J. An algorithm to assess the need for
clinical Monte Carlo dose calculation for small proton therapy fields based on
quantification of tissue heterogeneity. Med Phys. 2013;40(8):081704.
41. Grassberger C, Daartz J, Dowdell S, Ruggieri T, Sharp G, Paganetti H. Quantification of
proton dose calculation accuracy in the lung. International journal of radiation oncology,
biology, physics. 2014;89(2):424-30.
42. Maes D, Saini J, Zeng J, Rengan R, Wong T, Bowen SR. Advanced proton beam
dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer.
Translational lung cancer research. 2018;7(2):114-21.
43. Schuemann J, Shin J, Perl J, Grassberger C, Verburg J, Faddegon B, et al. SU-E-T-500:
Pencil-Beam versus Monte Carlo Based Dose Calculation for Proton Therapy Patients
with Complex Geometries. Clinical Use of the TOPAS Monte Carlo System. Med Phys.
2012;39(6Part18):3820.
44. Schuemann J, Giantsoudi D, Grassberger C, Moteabbed M, Min CH, Paganetti H.
Assessing the Clinical Impact of Approximations in Analytical Dose Calculations for
Proton Therapy. International journal of radiation oncology, biology, physics.
2015;92(5):1157-64.
45. Hong L, Goitein M, Bucciolini M, Comiskey R, Gottschalk B, Rosenthal S, et al. A pencil
beam algorithm for proton dose calculations. Phys Med Biol. 1996;41(8):1305-30.
46. Schaffner B, Pedroni E, Lomax A. Dose calculation models for proton treatment planning
using a dynamic beam delivery system: an attempt to include density heterogeneity effects
in the analytical dose calculation. Phys Med Biol. 1999;44(1):27-41.
47. Saini J, Traneus E, Maes D, Regmi R, Bowen SR, Bloch C, et al. Advanced Proton Beam
Dosimetry Part I: review and performance evaluation of dose calculation algorithms.
Transl Lung Cancer Res. 2018;7(2):171-9.
48. Fippel M, Soukup M. A Monte Carlo dose calculation algorithm for proton therapy. Med
Phys. 2004;31(8):2263-73.

106

49. Taylor PA, Kry SF, Followill DS. Pencil Beam Algorithms Are Unsuitable for Proton
Dose Calculations in Lung. International journal of radiation oncology, biology, physics.
2017.
50. Widesott L, Lorentini S, Fracchiolla F, Farace P, Schwarz M. Improvements in pencil
beam scanning proton therapy dose calculation accuracy in brain tumor cases with a
commercial Monte Carlo algorithm. Physics in Medicine & Biology. 2018;63(14):145016.
51. Sun B, Lam D, Yang D, Grantham K, Zhang T, Mutic S, et al. A machine learning
approach to the accurate prediction of monitor units for a compact proton machine. Med
Phys. 2018;45(5):2243-51.
52. Grewal HS, Chacko MS, Ahmad S, Jin H. Prediction of the output factor using machine
and deep learning approach in uniform scanning proton therapy. Journal of Applied
Clinical Medical Physics. 2020;21(7):128-34.
53. Kooy HM, Rosenthal SJ, Engelsman M, Mazal A, Slopsema RL, Paganetti H, et al. The
prediction of output factors for spread-out proton Bragg peak fields in clinical practice.
Physics in Medicine & Biology. 2005;50(24):5847.
54. Thummerer A, Zaffino P, Meijers A, Marmitt GG, Seco J, Steenbakkers RJ, et al.
Comparison of CBCT based synthetic CT methods suitable for proton dose calculations
in adaptive proton therapy. Physics in Medicine & Biology. 2020;65(9):095002.
55. Kurz C, Maspero M, Savenije MH, Landry G, Kamp F, Pinto M, et al. CBCT correction
using a cycle-consistent generative adversarial network and unpaired training to enable
photon and proton dose calculation. Physics in Medicine & Biology. 2019;64(22):225004.
56. Hansen DC, Landry G, Kamp F, Li M, Belka C, Parodi K, et al. ScatterNet: a convolutional
neural

network

for

cone‐beam

CT

intensity

correction.

Medical

physics.

2018;45(11):4916-26.
57. Landry G, Hansen D, Kamp F, Li M, Hoyle B, Weller J, et al. Comparing Unet training
with three different datasets to correct CBCT images for prostate radiotherapy dose
calculations. Physics in Medicine & Biology. 2019;64(3):035011.

107

58. Thummerer A, de Jong BA, Zaffino P, Meijers A, Marmitt GG, Seco J, et al. Comparison
of the suitability of CBCT-and MR-based synthetic CTs for daily adaptive proton therapy
in head and neck patients. Physics in Medicine & Biology. 2020;65(23):235036.
59. Harms J, Lei Y, Wang T, McDonald M, Ghavidel B, Stokes W, et al. Cone‐beam CT‐
derived relative stopping power map generation via deep learning for proton radiotherapy.
Medical Physics. 2020;47(9):4416-27.
60. Sonke J-J, Aznar M, Rasch C, editors. Adaptive radiotherapy for anatomical changes.
Seminars in radiation oncology; 2019: Elsevier.
61. Wu C, Nguyen D, Schuemann J, Mairani A, Pu Y, Jiang S. Applications of Artificial
Intelligence in Particle Radiotherapy. arXiv preprint arXiv:210203061. 2021.
62. Goodfellow IJ, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, et al.
Generative adversarial networks. arXiv preprint arXiv:14062661. 2014.
63. Ronneberger O, Fischer P, Brox T, editors. U-net: Convolutional networks for biomedical
image segmentation. International Conference on Medical image computing and
computer-assisted intervention; 2015: Springer.
64. Zhu J-Y, Park T, Isola P, Efros AA, editors. Unpaired image-to-image translation using
cycle-consistent adversarial networks. Proceedings of the IEEE international conference
on computer vision; 2017.
65. Carlson JNK, Park JM, Park S-Y, Park JI, Choi Y, Ye S-J. A machine learning approach
to the accurate prediction of multi-leaf collimator positional errors. Physics in Medicine
and Biology. 2016;61(6):2514-31.
66. Breiman L. Random Forests. Machine Learning. 2001;45(1):5-32.
67. Kuhn M, Weston S, Keefer C, Coulter N, Quinlan R. Cubist: rule-and instance-based
regression modeling. R package version 00. 2014;13.
68. Valdes G, Scheuermann R, Hung CY, Olszanski A, Bellerive M, Solberg TD. A
mathematical framework for virtual IMRT QA using machine learning. Medical Physics.
2016;43(7):4323-34.

108

69. Tibshirani R. Regression Shrinkage and Selection Via the Lasso. Journal of the Royal
Statistical Society: Series B (Methodological). 1996;58(1):267-88.
70. Laboratories R. RayStation 6 User Manual. 2017(No. RSL-D-RS-6.0-USM-EN-1.0-201612-22).
71. Sorriaux J, Testa M, Paganetti H, Orban de Xivry J, Lee JA, Traneus E, et al. Experimental
assessment of proton dose calculation accuracy in inhomogeneous media. Phys Med.
2017;38:10-5.
72. Smith BR, Hyer DE, Hill PM, Culberson WS. Secondary neutron dose from a dynamic
collimation system during intracranial pencil beam scanning proton therapy: a Monte
Carlo investigation. International Journal of Radiation Oncology* Biology* Physics.
2019;103(1):241-50.
73. Brenner DJ, Elliston CD, Hall EJ, Paganetti H. Reduction of the secondary neutron dose
in passively scattered proton radiotherapy, using an optimized pre-collimator/collimator.
Physics in medicine and biology. 2009;54(20):6065-78.
74. Bäumer C, Plaude S, Khalil DA, Geismar D, Kramer P-H, Kröninger K, et al. Clinical
Implementation of Proton Therapy Using Pencil-Beam Scanning Delivery Combined
With Static Apertures. Frontiers in Oncology. 2021;11:1377.
75. Zhang Y, Yang Z, Jiang J, Dai X, Qin P, Guo S, et al. Design Analysis and Experimental
Study of Robotic Chair for Proton Heavy Ion Radiotherapy. Applied Bionics and
Biomechanics. 2019;2019:6410941.
76. Zhang X, Hsi WC, Yang F, Wang Z, Sheng Y, Sun J, et al. Development of an isocentric
rotating chair positioner to treat patients of head and neck cancer at upright seated position
with multiple nonplanar fields in a fixed carbon-ion beamline. Med Phys.
2020;47(6):2450-60.
77. Via R, Pella A, Romanò F, Fassi A, Ricotti R, Tagaste B, et al. A platform for patient
positioning and motion monitoring in ocular proton therapy with a non-dedicated
beamline. Physica Medica. 2019;59:55-63.

109

78. Ciocca M, Magro G, Mastella E, Mairani A, Mirandola A, Molinelli S, et al. Design and
commissioning of the non-dedicated scanning proton beamline for ocular treatment at the
synchrotron-based CNAO facility. Med Phys. 2019;46(4):1852-62.
79. Nichiporov D, Hsi W, Farr J. Beam characteristics in two different proton uniform
scanning systems: A side-by-side comparison. Medical Physics. 2012;39(5):2559-68.
80. Miller RW, Raubitschek AA, Harrington FS, van de Geijn J, Ovadia J, Glatstein E. An
isocentric chair for the simulation and treatment of radiation therapy patients. International
journal of radiation oncology, biology, physics. 1991;21(2):469-73.
81. Kang M, Huang S, Solberg TD, Mayer R, Thomas A, Teo BK, et al. A study of the beamspecific interplay effect in proton pencil beam scanning delivery in lung cancer. Acta
Oncol. 2017;56(4):531-40.
82. Dowdell S, Grassberger C, Sharp GC, Paganetti H. Interplay effects in proton scanning
for lung: a 4D Monte Carlo study assessing the impact of tumor and beam delivery
parameters. Phys Med Biol. 2013;58(12):4137-56.
83. Botas P, Grassberger C, Sharp G, Paganetti H. Density overwrites of internal tumor
volumes in intensity modulated proton therapy plans for mobile lung tumors. Phys Med
Biol. 2017.
84. Soukup M, Fippel M, Alber M. A pencil beam algorithm for intensity modulated proton
therapy derived from Monte Carlo simulations. Phys Med Biol. 2005;50(21):5089-104.
85. Chen WZ, Xiao Y, Li J. Impact of dose calculation algorithm on radiation therapy. World
J Radiol. 2014;6(11):874-80.
86. Paganetti H. Monte Carlo simulations will change the way we treat patients with proton
beams today. Br J Radiol. 2014;87(1040).
87. Lee E, Zeng J, Miyaoka RS, Saini J, Kinahan PE, Sandison GA, et al. Functional lung
avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry
of a precision radiation oncology strategy. Med Phys. 2017;44(7):3418-29.

110

88. Zhang Y, Huth I, Wegner M, Weber DC, Lomax AJ. An evaluation of rescanning
technique for liver tumour treatments using a commercial PBS proton therapy system.
Radiotherapy and oncology. 2016;121(2):281-7.
89. Bernatowicz K, Lomax AJ, Knopf A. Comparative study of layered and volumetric
rescanning for different scanning speeds of proton beam in liver patients. Physics in
Medicine & Biology. 2013;58(22):7905.
90. Lin L, Huang S, Kang M, Hiltunen P, Vanderstraeten R, Lindberg J, et al. A benchmarking
method to evaluate the accuracy of a commercial proton monte carlo pencil beam scanning
treatment planning system. J Appl Clin Med Phys. 2017;18(2):44-9.
91. Dowdell S, Grassberger C, Paganetti H. Four-dimensional Monte Carlo simulations
demonstrating how the extent of intensity-modulation impacts motion effects in proton
therapy lung treatments. Med Phys. 2013;40(12):121713.
92. Meier G, Besson R, Nanz A, Safai S, Lomax AJ. Independent dose calculations for
commissioning, quality assurance and dose reconstruction of PBS proton therapy. Physics
in Medicine and Biology. 2015;60(7):2819-36.
93. Zhu XR, Li Y, Mackin D, Li H, Poenisch F, Lee AK, et al. Towards Effective and Efficient
Patient-Specific Quality Assurance for Spot Scanning Proton Therapy. Cancers.
2015;7(2):631-47.
94. Scandurra D, Albertini F, van der Meer R, Meier G, Weber DC, Bolsi A, et al. Assessing
the quality of proton PBS treatment delivery using machine log files: comprehensive
analysis of clinical treatments delivered at PSI Gantry 2. Phys Med Biol. 2016;61(3):117181.
95. Li H, Sahoo N, Poenisch F, Suzuki K, Li Y, Li X, et al. Use of treatment log files in spot
scanning proton therapy as part of patient-specific quality assurance. Medical Physics.
2013;40(2):021703.
96. Belosi MF, van der Meer R, Garcia de Acilu Laa P, Bolsi A, Weber DC, Lomax AJ.
Treatment log files as a tool to identify treatment plan sensitivity to inaccuracies in
scanned proton beam delivery. Radiotherapy and Oncology. 2017;125(3):514-9.

111

97. Tomori S, Kadoya N, Takayama Y, Kajikawa T, Shima K, Narazaki K, et al. A deep
learning-based prediction model for gamma evaluation in patient-specific quality
assurance. Medical Physics. 2018;45(9):4055-65.
98. Shiba E, Saito A, Furumi M, Murakami Y, Ohguri T, Tsuneda M, et al. Predictive gamma
passing rate by dose uncertainty potential accumulation model. Medical Physics.
2019;46(2):999-1005.
99. Guterres Marmitt G, Pin A, Ng Wei Siang K, Janssens G, Souris K, Cohilis M, et al.
Platform for automatic patient quality assurance via Monte Carlo simulations in proton
therapy. Phys Med. 2020;70:49-57.
100. Toscano S, Souris K, Gomà C, Barragán-Montero A, Puydupin S, Stappen FV, et al.
Impact of machine log-files uncertainties on the quality assurance of proton pencil beam
scanning treatment delivery. Physics in Medicine & Biology. 2019;64(9):095021.
101. Fabian Pedregosa GV, Alexandre Gramfort, Vincent Michel, Bertrand Thirion, Olivier
Grisel, Mathieu Blondel, Peter Prettenhofer, Ron Weiss, Vincent Dubourg, Jake
Vanderplas, Alexandre Passos, David Cournapeau, Matthieu Brucher, Matthieu Perrot,
Édouard Duchesnay. Scikit-learn: Machine Learning in Python. Journal of Machine
Learning Research. 2011;12:2825-30.
102. Saunders C, Gammerman A, Vovk V. Ridge regression learning algorithm in dual
variables. 1998.
103. Ari B, Güvenir HA. Clustered linear regression. Knowledge-Based Systems.
2002;15(3):169-75.
104. Geurts P, Ernst D, Wehenkel L. Extremely randomized trees. Machine Learning.
2006;63(1):3-42.
105. Murtagh F. Multilayer perceptrons for classification and regression. Neurocomputing.
1991;2(5):183-97.
106. Rumelhart DE, Hinton GE, Williams RJ. Learning representations by back-propagating
errors. Nature. 1986;323(6088):533-6.

112

107. Kingma D, Ba J. Adam: A method for stochastic optimization. arXiv 2014. arXiv preprint
arXiv:14126980. 2014.
108. Agostinelli S, Allison J, Amako Ka, Apostolakis J, Araujo H, Arce P, et al. GEANT4—a
simulation toolkit. Nuclear instruments and methods in physics research section A:
Accelerators, Spectrometers, Detectors and Associated Equipment. 2003;506(3):250-303.
109. Jia X, Schümann J, Paganetti H, Jiang SB. GPU-based fast Monte Carlo dose calculation
for proton therapy. Physics in Medicine & Biology. 2012;57(23):7783.
110. Wan Chan Tseung H, Ma J, Beltran C. A fast GPU‐based Monte Carlo simulation of
proton transport with detailed modeling of nonelastic interactions. Medical physics.
2015;42(6Part1):2967-78.

113

